

1 **Title:**

2 Elucidating the basis for permissivity of the MT-4 T-cell line to replication of an HIV-1  
3 mutant lacking the gp41 cytoplasmic tail  
4  
5  
6  
7

8 **Authors and affiliations:**

9 Melissa V. Fernandez<sup>1</sup>, Huxley K. Hoffman<sup>2</sup>, Nairi Pezeshkian<sup>2</sup>, Philip R. Tedbury<sup>1</sup>,  
10 Schuyler B. van Engelenburg<sup>2</sup>, and Eric O. Freed<sup>1\*</sup>  
11

12 <sup>1</sup> HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer  
13 Institute, Frederick, MD 21702, USA

14 <sup>2</sup> Molecular and Cellular Biophysics Program, Department of Biological Sciences,  
15 University of Denver, Denver, CO 80210, USA  
16

17 \*Author for correspondence (efreed@mail.nih.gov)  
18

19 **Institutional addresses:**

20 National Cancer Institute  
21 HIV Dynamics and Replication Program  
22 1050 Boyles St.  
23 Building 535, Room 110  
24 Frederick, MD 21702  
25

26 Department of Biological Sciences  
27 Seeley G. Mudd Building  
28 2101 E. Wesley Ave.  
29 Denver, CO 80210  
30  
31

32 **Abstract**

33

34 HIV-1 encodes an envelope glycoprotein (Env) that contains a long cytoplasmic tail (CT)  
35 harboring trafficking motifs implicated in Env incorporation into virus particles and viral  
36 transmission. In most physiologically relevant cell types, the gp41 CT is required for  
37 HIV-1 replication, but in the MT-4 T-cell line the gp41 CT is not required for a spreading  
38 infection. To help elucidate the role of the gp41 CT in HIV-1 transmission, in this study  
39 we investigated the viral and cellular factors that contribute to the permissivity of MT-4  
40 to gp41 CT truncation. We found that the kinetics of HIV-1 production are faster in MT-4  
41 than in the other T-cell lines tested, but MT-4 express equivalent amounts of HIV-1  
42 proteins on a per-cell basis relative to cells not permissive to CT truncation. MT-4  
43 express higher levels of plasma-membrane-associated Env than non-permissive cells  
44 and Env internalization from the plasma membrane is slower compared to another T-  
45 cell line, SupT1. Paradoxically, despite the high levels of Env on the surface of MT-4,  
46 two-fold less Env is incorporated into virus particles in MT-4 compared to SupT1. Cell-  
47 to-cell transmission between co-cultured 293T and MT-4 is higher than in co-cultures of  
48 293T with most other T-cell lines tested, indicating that MT-4 are highly susceptible to  
49 this mode of infection. These data help to clarify the long-standing question of how MT-  
50 4 cells overcome the requirement for the HIV-1 gp41 CT and support a role for gp41  
51 CT-dependent trafficking in Env incorporation and cell-to-cell transmission in  
52 physiologically relevant cell lines.

53

54 **Importance**

55

56 The HIV-1 Env cytoplasmic tail (CT) is required for efficient Env incorporation into  
57 nascent particles and viral transmission in primary CD4<sup>+</sup> T cells. The MT-4 T-cell line  
58 has been reported to support multiple rounds of infection of HIV-1 encoding a gp41 CT  
59 truncation. Uncovering the underlying mechanism of MT-4 T-cell line permissivity to  
60 gp41 CT truncation would provide key insights into the role of the gp41 CT in HIV-1  
61 transmission. This study reveals that multiple factors contribute to the unique ability of a  
62 gp41 CT truncation mutant to spread in cultures of MT-4 cells. The lack of a  
63 requirement for the gp41 CT in MT-4 is associated with the combined effects of rapid  
64 HIV-1 protein production, high levels of cell-surface Env expression, and increased  
65 susceptibility to cell-to-cell transmission compared to non-permissive cells.

66

67

68 **Keywords:** HIV-1, Env, gp41, cytoplasmic tail, virological synapse, transmission, HTLV-  
69 I, Tax

## 70 Introduction

71  
72 HIV-1 Env is initially synthesized in the endoplasmic reticulum (ER) as a polyprotein  
73 precursor, gp160, which is cleaved during trafficking through the Golgi apparatus to  
74 generate the mature surface Env subunit gp120 and the transmembrane subunit gp41  
75 (1, 2). The two subunits are non-covalently linked to form a trimeric gp120:gp41  
76 heterodimer in the functional Env glycoprotein complex. The mature, trimeric Env  
77 complex traffics via the secretory pathway to the plasma membrane (PM), the site of  
78 viral assembly and budding. Env is expressed on the surface of infected cells and is  
79 incorporated into virus particles where it is embedded in the viral envelope.

80  
81 The two subunits of Env are responsible for different functions of the glycoprotein  
82 complex. The gp120 subunit promotes particle attachment and entry by binding to  
83 receptor (CD4) and co-receptor (CXCR4 or CCR5). The gp41 subunit comprises three  
84 domains: an ectodomain that associates with gp120 and contains the determinants  
85 critical for membrane fusion, a transmembrane domain that anchors Env in the lipid  
86 bilayer, and a cytoplasmic tail (CT) that regulates a number of aspects of Env function.  
87 While the principal functions of the Env complex are well characterized, and it is clear  
88 that the gp41 CT regulates Env incorporation into virions, the precise role of the CT in  
89 Env biology remains poorly understood.

90  
91 HIV-1 is transmitted to target cells *in vitro* and *in vivo* via either cell-free or cell-to-cell  
92 (C-C) infection (3, 4). Cell-free infection occurs when virions that are not associated with  
93 the virus-producing cell bind and enter uninfected target cells. C-C infection is defined  
94 as direct transmission of nascent particles at points of contact, known as virological  
95 synapses (VSs), between infected and uninfected cells. Studies have established that,  
96 *in vitro*, viral dissemination by C-C transmission is a highly efficient mode of viral  
97 transfer relative to cell-free infection (5-9). However, the relative contribution of cell-free  
98 vs C-C transmission to viral spread *in vivo* is less clear. In most cell types, viral  
99 transmission requires CT-dependent localization of Env to viral assembly sites (10-13)  
100 and Env binding to CD4 and co-receptor. A hallmark of C-C spread is the accumulation  
101 of viral proteins, in particular Gag and Env, at the VS (5, 6, 11, 14). How Env is directed  
102 to the VS is not well understood; further elucidation of this process is fundamental to our  
103 ability to design therapies capable of blocking C-C transmission.

104  
105 The lentiviral gp41 CT is very long compared to those of other retroviruses; it contains  
106 150 amino acids in the case of HIV-1 and harbors trafficking motifs implicated in Env  
107 recycling, incorporation, and viral transmission. The gp41 CT contains a highly  
108 conserved YxxΦ motif (with Φ representing a hydrophobic amino acid) known to interact  
109 with host cell clathrin adaptor protein complex 2 (AP-2) and mediate fast internalization  
110 of Env via clathrin-mediated endocytosis (2). The gp41 CT contains several other well-  
111 conserved tyrosine and dileucine motifs that may also play a role in Env trafficking and  
112 subcellular localization (2). The high degree of conservation in both the length of the  
113 gp41 CT and the YxxΦ motif suggests that these features play key roles in viral  
114 transmission. It is currently unclear whether Env recycling from the PM prior to  
115 incorporation into the assembling Gag lattice is a requisite step in Env incorporation.

116 Recent evidence suggests a role for recycling in Env incorporation (15-17) and many  
117 studies have explored the role of trafficking motifs in the gp41 CT in promoting the  
118 proper spatio-temporal localization of Env during assembly (1, 2, 18, 19), but the role of  
119 Env recycling in Env incorporation is not well-defined.

120  
121 Wild-type (WT) HIV-1 has an average of ~10 Env trimers per virion (20) and truncation  
122 of the gp41 CT generally results in a 10-fold decrease in Env incorporation in  
123 physiologically relevant cell types (which we refer to as being non-permissive to gp41  
124 CT truncation) (21). The sparsity of Env on HIV-1 particles suggests that Env  
125 incorporation is tightly regulated. The degree of regulation seems to be cell-type and CT  
126 dependent. For example, in the non-permissive T-cell line CEM-A, WT Env is localized  
127 at the neck of the budding particle while truncation of the gp41 CT results in a more  
128 uniform Env distribution around the virus particle (19). In the permissive COS7  
129 fibroblast-like cell line, both WT and CT-truncated Env are evenly distributed around the  
130 virus particle. CT-dependent endocytosis of WT Env from the PM is more active in  
131 CEM-A than in COS7, suggesting that Env recycling regulates Env distribution on the  
132 virus particle. Importantly, in both cell lines, incorporation of the gp41 CT-truncated  
133 mutant was reduced compared to the WT, consistent with the essential role for the CT  
134 in trapping Env in the assembling Gag lattice (22). These data highlight the multifaceted  
135 role of the gp41 CT in regulating Env incorporation and the cell-type dependent  
136 utilization of the CT in viral assembly.

137  
138 A functional interaction between the gp41 CT and the matrix (MA) domain of the Gag  
139 polyprotein has been postulated to play an important role in capturing Env during viral  
140 assembly (23, 24). Compelling evidence for the trapping of the gp41 CT by the Gag  
141 lattice has been previously demonstrated by various studies showing the clustering of  
142 Env trimers at sites of virus assembly (10, 12, 19, 22) and retention of full-length Env,  
143 but not CT-truncated Env, in detergent-stripped Gag virus-like particles (25). Further  
144 evidence for the trapping of the gp41 CT by the Gag lattice is provided by the ability of  
145 single amino acid changes in MA to block WT Env incorporation (26-33). Truncation of  
146 the gp41 CT reverses the Env incorporation block imposed by these point mutations in  
147 MA (26, 29, 31, 33). Similarly, Env incorporation is inhibited by small intragenic  
148 deletions in MA or deletion of the globular domain of MA, and this inhibition is relieved  
149 by truncation of the gp41 CT (31, 34). Highlighting the importance of MA- gp41 CT  
150 interactions, a small deletion in the gp41 CT that inhibits Env incorporation is rescued  
151 by a single amino acid change in MA (35). Further underscoring the intimate  
152 relationship between MA and the gp41 CT, truncation of the gp41 CT abrogates Gag's  
153 ability to repress premature fusion of Env with the target cell membrane (12, 36, 37).  
154 Recent studies have demonstrated an important role for trimerization of the MA domain  
155 of Gag in the formation of a Gag lattice that accommodates the long gp41 CT during  
156 Env incorporation (27, 28, 38). While evidence of the relationship between the gp41 CT  
157 and MA is well appreciated, the precise mechanism of how Env is incorporated into the  
158 assembling Gag lattice is not well understood.

159  
160 Our understanding of the function of the gp41 CT and MA in Env incorporation suggests  
161 four general models of Env incorporation: 1) passive incorporation (Env incorporation

162 does not require its concentration at assembly sites), 2) Gag-Env co-targeting (Gag and  
163 Env are both targeted to an assembly platform, such as a membrane microdomain), 3)  
164 direct Gag-Env interaction (Gag directly binds the gp41 CT, thereby capturing it into  
165 assembling virions), and 4) indirect Gag-Env interaction (a host factor serves as a  
166 bridge between Gag and Env for the capture of Env by the assembling Gag lattice) (1,  
167 23). These models are not mutually exclusive; for example, Env could colocalize with  
168 Gag at sites of virus assembly and then be captured by the Gag lattice via direct  
169 interactions between MA and the gp41 CT, and other combinations of these models can  
170 be readily envisioned. Interestingly, even foreign viral glycoproteins have been shown to  
171 cluster at HIV-1 assembly sites in the context of pseudotype particle formation (39, 40).

172  
173 The unusual ability of certain T-cell lines (notably MT-4, C8166, and M8166) to be  
174 highly susceptible to HIV-1 infection and permissive to loss of certain viral protein  
175 functions is incompletely understood. In particular, MT-4 are known to be permissive,  
176 relative to other T-cell lines, to deletion of the gp41 CT (14, 21, 29, 31, 33, 38, 41-45),  
177 loss of integrase (IN) function (46, 47), disruption of proper capsid (CA) multimerization  
178 (48), deletion of Nef (49), and a large MA deletion (34). A functional IN protein is  
179 required for productive HIV-1 replication in a majority of cell lines and human peripheral  
180 blood mononuclear cells (hPBMCs) (47). MT-4 and C8166 are known to be permissive  
181 to type I IN mutations (mutations in IN that specifically block viral DNA integration into  
182 the host cell genome) while Jurkat E6.1 and hPBMCs are non-permissive to defects in  
183 integration (47). It was recently reported that MT-4 and C8166 are likely permissive to  
184 type I IN mutations due to HTLV-I Tax expression inducing NF- $\kappa$ B protein recruitment to  
185 the HIV-1 LTR on unintegrated HIV-1 DNA (46). Furthermore, it was previously  
186 suggested by Emerson et al. (14) that HTLV-I Tax expression may contribute to MT-4  
187 permissivity by causing potent and chronic activation of NF- $\kappa$ B signaling (50), resulting  
188 in transactivation of the HIV-1 LTR (51). The ability of MT-4 to support rapid replication  
189 of HIV-1 and gain second-site compensatory mutations unlikely to be acquired in less-  
190 permissive cells has led to the use of this cell line for selection experiments with a wide  
191 variety of defective MA and CA mutants (29, 48, 52-54). Uncovering the underlying  
192 mechanisms of MT-4 cell line permissivity is important because of the frequent use of  
193 this cell line in HIV-1 replication studies (13, 55-57).

194  
195 In this study, we examined a number of factors involved in viral replication and spread in  
196 cells both permissive (i.e., MT-4) and non-permissive (i.e., all other T-cell lines tested)  
197 for gp41 CT truncation. Our results show that HTLV-I Tax expression is not the sole  
198 determinant of permissivity to gp41 CT truncation. Rather, high surface Env expression,  
199 rapid kinetics of HIV protein production, and efficient C-C transmission likely contribute  
200 to the MT-4 permissivity to CT-truncation.

201

## 202 Results

203

### 204 Lineage and validation of cell lines used to interrogate T-cell line permissivity to 205 replication of an HIV-1 mutant lacking the gp41 CT.

206 To investigate the mechanistic basis for the permissivity of MT-4 cells to replication of a  
207 gp41 CT-truncation mutant, a panel of five T-cell lines were selected based on their  
208 origins (Fig. 1) and previously reported permissivity, or lack thereof, to gp41 CT  
209 truncation. Previous studies have reported that MT-4 (14, 21, 29, 31, 33, 38, 41-45) and  
210 M8166 (58) are permissive to truncation of the gp41 CT, and it is established that  
211 hPBMCs, SupT1, and Jurkat E6.1 are not permissive (14, 21). Therefore, two HTLV-1<sup>-</sup>  
212 lymphoma-derived cell lines, SupT1 (59) and Jurkat E6.1 (60) (Fig. 1A-B); and three  
213 HTLV-1-transformed lines, MT-4 (61), C8166 (62), and M8166 (Fig. 1C-D) were  
214 selected for this study. The cell line lineage and HTLV-I particle and RNA production  
215 status of each cell line are shown in Fig 1. C8166, M8166, and MT-4 all express HTLV-I  
216 RNA but do not produce viral particles. Due to the presence of HTLV-I RNA, they do  
217 express the HTLV-I Tax protein (43, 63, 64). SupT1 and Jurkat E6.1 do not express  
218 HTLV-I RNA or proteins (59, 60).

219

220 Short tandem repeat (STR) profiling was utilized to validate the identity of all the cell  
221 lines in our T-cell panel (Table 1). The MT-4 STR profile, recently validated by functional  
222 assays, morphological analysis, and assessment of HTLV-I Tax protein expression (43),  
223 was an exact match to the Cellosaurus reference profile (Table 1). Jurkat E6.1 and  
224 SupT1 STR profiles were both close matches to the published STR profiles. The STR  
225 profile revealed some genetic instability in the SupT1 line compared to SupT1-CCR5,  
226 indicated by the presence of extra, lower-intensity alleles at several gene loci (data not  
227 shown). Overall, the STR profile of our SupT1 cell line was a 95% match to the SupT1-  
228 CCR5 line, confirming the identity of our laboratory SupT1 line. The Jurkat E6.1 line  
229 also displayed some genetic instability (data not shown), which accounts for its  
230 imperfect match to the Cellosaurus reference profile.

231

232 M8166 is a subclone of C8166 (Fig. 1D), and therefore these two lines share the same  
233 STR profile (Table 1), which was a ~98% match to the cell line profile published in the  
234 Cellosaurus database and in a separate report (65). To further confirm the identity of the  
235 M8166 and C8166 cell lines, they were assessed for their capacity to host replication of  
236 WT SIVmac239 (Fig. 2). The C8166 line has been reported to exhibit a block to efficient  
237 SIV replication (66), whereas M8166 is reportedly capable of hosting multiple rounds of  
238 SIVmac239 replication (67). Consistent with these reports, SIVmac239 did not establish  
239 a spreading infection in C8166 (Fig. 2a) while it did in M8166 (Fig. 2B). Together, the  
240 STR profile and capacity of M8166, but not C8166, to support multiple rounds of  
241 SIVmac239 replication confirm the identity of the C8166 and M8166 cell lines used in  
242 this study.

243

### 244 MT-4 is the only T-cell line tested in this study that is permissive to the gp41 CT 245 truncation mutant CTdel144.

246 HIV-1 replication in most T-cell lines is abrogated by truncation of the gp41 CT (14, 21),  
247 but several studies have demonstrated that the MT-4 cell line is able to propagate a

248 gp41 CT-deleted mutant (14, 21, 29, 31, 33, 38, 41-45). To evaluate the ability of the  
249 CTdel144 mutant, which lacks 144 amino acids from the gp41 CT (26), to replicate in  
250 HTLV-I-transformed T-cell lines, MT-4, C8166 and M8166 cells were transfected with  
251 the WT pNL4-3 molecular clone or the CTdel144 derivative, to initiate a spreading  
252 infection (Fig. 3A). MT-4, C8166, and M8166 (Fig. 3B-D) supported rapid WT HIV-1  
253 replication with supernatant HIV-1 reverse transcriptase (RT) activity detectable within  
254 3-5 days post-transfection (Fig. 3B). Replication of HIV-1 in T-cell lines not permissive  
255 to truncation of the gp41 CT - or in phytohemagglutinin (PHA)-activated PBMCs isolated  
256 from healthy hPBMCs - was markedly slower than in MT-4 cells (Fig. 3E-G compared to  
257 Fig. 3B). Consistent with previous reports (14, 21, 29, 31, 33, 38, 41-45), the MT-4 cell  
258 line also supported replication of the CTdel144 mutant. In contrast, neither of the other  
259 two HTLV-1-transformed T-cell lines (C8166 and M8166), the two HTLV-1<sup>-</sup> lymphoma-  
260 derived cell lines (SupT1 and Jurkat E6.1), or hPBMCs supported replication of  
261 CTdel144 (Fig. 3B compared to Fig. 3C-G). Therefore, under these standard conditions,  
262 MT-4 is unique among the T-cell lines tested here in their capacity to support multiple  
263 rounds of CTdel144 replication.  
264

#### 265 *NF-κB-target gene expression in Tax-expressing T-cell lines is higher than in SupT1.*

266 To determine the relative levels of Tax expression in MT-4, C8166 and M8166, western  
267 blot analysis of cell lysates was performed (Fig. 4A). To control for antibody specificity,  
268 two sets of controls were included: 1) a panel of adult T-cell leukemia (ATL) cells  
269 previously reported to have lost Tax expression (68), and 2) 293T cells transfected with  
270 a Tax expression vector (Fig. 4A). Western blot analysis indicated that C8166  
271 expressed substantially more Tax protein than MT-4 or M8166, while a small amount of  
272 Tax expression in the ATL-55T cell line was detectable.  
273

274 Tax is a known oncogene whose expression induces rapid senescence through potent  
275 and persistent NF-κB hyperactivation and upregulation of NF-κB-regulated genes (68,  
276 69). To ascertain whether Tax expression in these cells has resulted in hyperactivation  
277 of NF-κB signaling, Illumina RNA-seq was employed to measure the RNA expression of  
278 NF-κB-dependent and -independent genes in untreated cells. A panel of NF-κB target  
279 genes was selected from a database of genes activated by NF-κB; these included  
280 immunoreceptor genes and genes involved in proliferation, apoptosis, stress response,  
281 and cytokine-stimulation (70). A control panel of NF-κB-independent genes targeted by  
282 the IRF3 transcription factor was derived from the ENCODE Transcription Factors  
283 database (available on the Harmonizome search engine) for IRF3-target genes  
284 identified by ChIP-seq (71, 72). IRF3-target genes also targeted by NF-κB, identified by  
285 their presence in the NF-κB-target genes panel (70), were not used in the IRF3-  
286 dependent target gene analysis. Overall, NF-κB-target gene transcripts were  
287 upregulated in all three HTLV-I-transformed lines relative to SupT1 (Fig. 4B-D - left).  
288 IRF3-target genes were not consistently up- or down-regulated (Fig. 4B-D - right),  
289 consistent with a Tax-dependent chronic hyperactivation of NF-κB, but not IRF3,  
290 signaling in Tax-expressing cell lines. These data establish that Tax transactivation of  
291 the HIV-1 LTR is not solely responsible for MT-4 permissivity to gp41 CT truncation.  
292



293 *Viral entry mediated by full-length and CT-truncated Env is equivalent among HTLV-*  
294 *transformed T-cell lines.*

295 Binding of virion-associated Env to the CD4 receptor and CXCR4 or CCR5 co-receptor  
296 is an essential step for infection of human T cells by most strains of HIV-1. T-cell line  
297 tropic isolates, like NL4-3, use CXCR4 as their coreceptor. To determine whether high-  
298 level expression of CD4 or CXCR4 on the surface of MT-4 cells could contribute to the  
299 permissivity of this cell line to CT-truncated HIV-1, surface CD4 and CXCR4 was  
300 measured on the panel of T-cell lines (Fig. 5A-B). While MT-4 cells did express more  
301 CD4 and CXCR4 than C8166 or M8166, they expressed less CD4 than SupT1.  
302 Therefore, receptor and coreceptor expression levels do not account for the permissive  
303 phenotype exhibited by MT-4.  
304

305 To determine whether increased efficiency of viral entry contributes to MT-4  
306 permissivity, the  $\beta$ -lactamase (BlaM)-based viral entry assay was performed using virus  
307 bearing either VSV-G, WT HIV-1 Env, or the CTdel144 Env truncation mutant (Fig. 5C-  
308 F). Differences in viral entry mediated by VSV-G were not statistically significant  
309 between the cell lines (Fig. 5D). Entry mediated by WT HIV-1 Env was significantly  
310 lower in SupT1 than in the other T-cell lines, with MT-4 cells intermediate between  
311 Jurkat E6.1 and the other HTLV-1-transformed T-cell lines. Entry mediated by WT Env  
312 was not statistically different between MT-4 and Jurkat E6.1, C8166, and M8166 (Fig.  
313 5E). Entry mediated by CTdel144 was equivalent among all cell lines tested, with the  
314 exception of SupT1, which displayed restricted entry consistent with low susceptibility to  
315 cell-free HIV-1 infection (6). These results demonstrate that the permissivity of MT-4  
316 cells to the gp41 CT truncation mutant is not explained at the level of cell-free virus  
317 entry.  
318

319 *Kinetics of virus release in MT-4 are faster than in other T-cell lines tested.*

320 Because the kinetics of HIV-1 replication in MT-4 cells are more rapid than in the other  
321 T-cell lines tested, we hypothesized that the kinetics of HIV-1 gene expression might  
322 also be faster in MT-4 cells. An equal number of cells were transduced with equivalent  
323 amounts of VSV-G-pseudotyped Env<sup>-</sup> NL4-3 encoding eGFP in place of Nef (Fig. 6A-  
324 C). In this reporter virus, eGFP expression is under transcriptional control of the viral  
325 LTR; eGFP thus serves as a surrogate for LTR-mediated gene expression. Cells were  
326 analyzed for eGFP expression by flow cytometry at multiple time points post-  
327 transduction. We observed that a higher percentage of MT-4 cells expressed eGFP 24  
328 hours post-transduction relative to the other T-cell lines (Fig. 6A). The percentage of  
329 MT-4 expressing eGFP increased ~3-fold 48 hours post-transduction, whereas the other  
330 cell lines tested exhibited a ~2-fold increase in the number of eGFP<sup>+</sup> cells, with the  
331 exception of M8166, which exhibited only a minor increase in eGFP expression  
332 between 24 and 48 hours post-transduction. Therefore, the kinetics of HIV-1 protein  
333 production in MT-4 are faster relative to the other T-cell lines examined here.  
334

335 Enhanced virus production and release on a per-cell basis could contribute to the gp41  
336 CT-truncation permissive phenotype of MT-4 cells. To determine whether MT-4 express  
337 more HIV proteins than non-permissive cells, the eGFP median fluorescence intensity  
338 (MFI) was measured at different time points (Fig. 6B-C). At 24 hours post-transduction,

339 the MFI of MT-4 was less than that of SupT1, C8166, or M8166. At 48 hours post-  
340 transduction, the MT-4 MFI increased to that of C8166 and M8166, indicating that the  
341 HIV gene expression on a per-cell basis between MT-4 and C8166 is equivalent,  
342 consistent with the data of Emerson et al (14). The finding that SupT1, a Tax<sup>-</sup> non-  
343 permissive cell line, expressed more eGFP than MT-4 is inconsistent with the  
344 hypothesis that MT-4 are permissive to CT-truncation due to overall enhanced protein  
345 production per cell relative to non-permissive cells.

346  
347 To explore the role of viral protein production kinetics in virus output, virus release in the  
348 T-cell panel was measured. Cells were transduced with Env<sup>-</sup> VSV-G-pseudotyped NL4-  
349 3 and HIV-1 RT released into the supernatant was measured 42 hours post-  
350 transduction (Fig. 6D). Consistent with increased kinetics of HIV-1 protein expression  
351 compared to the other T-cell lines in the panel, HIV-1 RT production was highest for  
352 MT-4 compared to other cell lines. Taken together, these data indicate that on a per-cell  
353 basis, individual MT-4 cells do not exhibit higher steady-state cell-associated viral gene  
354 expression than the non-permissive cell lines tested here. However, MT-4 cultures  
355 release nearly three-fold more HIV-1 RT in a 42-hour period, indicating that the kinetics  
356 of HIV protein production in MT-4 cells are faster than in the other cell lines tested.

357  
358 *Env incorporation in MT-4 is inefficient.*

359 Because Env incorporation into virus particles is essential for viral infectivity, we next  
360 investigated the role of the gp41 CT in Env incorporation in SupT1 and MT-4. Env  
361 incorporation was determined by two methods, radio-immunoprecipitation (radio-IP) and  
362 western blot (Fig. 7A-C). Equivalent numbers of both MT-4 and SupT1 cells were  
363 transduced overnight with VSV-G-pseudotyped HIV-1 expressing either WT or  
364 CTdel144 Env and washed extensively the following morning to remove unabsorbed  
365 virus. Cell- and virus-containing supernatants were collected, lysed, and prepared for  
366 analysis as described in the Methods. Consistent with our previous report (21),  
367 truncation of the gp41 CT in a non-permissive T-cell line, SupT1, resulted in an  
368 approximately 10-fold decrease in Env incorporation, as measured by gp120 and gp41  
369 levels in virions, compared to WT (Fig. 7A). In contrast, in MT-4 cells, truncation of the  
370 gp41 CT resulted in an approximately 2-fold reduction in Env incorporation (Fig. 7B).  
371 We next tested whether higher levels of WT Env are incorporated into virions produced  
372 in MT-4 compared to SupT1 cells. Virus lysates were similarly prepared as in Fig. 7A-B,  
373 RT-normalized, subjected to SDS-PAGE, and Env band intensities were measured (Fig.  
374 7C). Surprisingly, MT-4 were found to incorporate less WT Env than SupT1. To gain  
375 more insight into why MT-4 incorporate less Env than the non-permissive SupT1 cell  
376 line, various parameters of viral assembly were determined (Fig. 7D-F). Env processing  
377 in MT-4 was lower than in SupT1 (Fig. 7D). The ratio of cell-associated gp120 to total  
378 Gag was also lower for MT-4 than SupT1 (Fig. 7E). Consistent with a previous report  
379 that examined other non-permissive T-cell lines (14), we observed that Gag processing  
380 in MT-4 is more efficient than in the non-permissive SupT1 (Fig. 7F). More rapid Gag  
381 processing is likely an indication of more rapid Gag trafficking, membrane association,  
382 and/or assembly, perhaps resulting in assembly of the Gag lattice before Env is  
383 recruited (19).

384

385 High infectivity of virions produced from MT-4 does not explain their permissivity to gp41  
386 CT truncation.

387 The surprising result that Env incorporation in MT-4 is inefficient relative to SupT1  
388 suggested that there is something inherently more efficient about viral transmission in  
389 the MT-4 cell line. To determine whether cell-free virions produced from MT-4 cells are  
390 more infectious than virions produced from the other cell lines in our panel, TZM-bl  
391 infectivity assays were performed (Fig. 8A-C). Cells were transduced with VSV-G-  
392 pseudotyped HIV-1 encoding either WT or CTdel144 Env and collected 42 hours post-  
393 transduction. RT-normalized virus supernatants from the T-cell panel were used to  
394 infect TZM-bl cells in parallel. Consistent with our findings that Env incorporation of the  
395 CT-truncated Env is reduced ~10-fold and ~2-fold in SupT1 and MT-4, respectively,  
396 cell-free infectivity was also reduced to a similar extent by the CTdel144 mutation (Fig.  
397 8A). Thus, under these conditions and with these cell lines, cell-free infectivity closely  
398 correlates with levels of virion-associated Env.

399  
400 To directly compare the infectivity between WT and CTdel144 virus produced from all  
401 five T-cell lines, TZM-bl cells were infected in parallel with the same RT-normalized  
402 virus produced as in Fig. 7A. SupT1 were used as the standard of comparison. We  
403 observed the infectivity of WT virus produced by all cells, with the exception of M8166,  
404 to be significantly lower than WT virus produced by SupT1 (Fig. 8B). Interestingly,  
405 CTdel144 virions produced in the non-permissive cell line M8166 exhibited ~3-fold  
406 higher levels of infectivity compared to MT-4 and C8166 (Fig. 8C), suggesting that cell-  
407 free infectivity is, at most, a minor contributing factor to the CT-permissive phenotype of  
408 MT-4.

409  
410 MT-4 express higher levels of cell surface CT-truncated Env than other T-cell lines  
411 tested. Because Env incorporation in MT-4 is reduced compared to the other T-cell lines  
412 tested, we next investigated whether Env is efficiently expressed on the cell surface of  
413 MT-4. To measure cell surface-associated Env, the T-cell panel was transduced with  
414 VSV-G pseudotyped WT or CTdel144 NL4-3 and fixed 42 hours later, a time point at  
415 which the cells would be expected to express HIV-1 proteins, but not display extensive  
416 syncytium formation. Fixed cells were then fluorescently labeled with anti-gp120  
417 antibodies and Env expression was measured by flow cytometry as a shift in the  
418 histogram relative to an Env<sup>-</sup> control (Fig. 9A). WT Env expression on MT-4 cells was  
419 higher than on the other cell lines tested (Fig. 9B). Consistent with the role of the gp41  
420 CT in regulating endocytosis (73-76), truncation of the gp41 CT enhanced cell-surface  
421 Env expression in all cell lines including MT-4, although in M8166 the increase was not  
422 statistically significant (Fig. 9B).

423  
424 The enhanced surface expression of Env observed in MT-4 cells could be explained by  
425 either defects in Env internalization or high levels of viral protein production relative to  
426 the other cell lines, resulting in high levels of cell-associated Env. Having established  
427 that MT-4 do not exhibit higher levels of LTR-mediated gene expression than some  
428 other cell lines in the panel, we sought to determine whether Env internalization is  
429 defective in MT-4. To confirm the higher levels of cell-associated Env on MT-4 relative  
430 to the nonpermissive SupT1 cell line, MT-4 and SupT1 cells were transduced with VSV-

431 G-pseudotyped HIV-1, pulse-chased with a fluorescently labeled anti-gp120 monovalent  
432 Fab probe and analyzed by confocal microscopy (Fig. 10A) (19). A monovalent Fab  
433 fragment was used to probe for Env levels to avoid bivalent antibody crosslinking of Env  
434 trimers, which has been shown to induce Env internalization (77). The anti-gp120 probe  
435 used in the pulse-chase assay labeled both the internalized pool of Env and surface  
436 Env. The total (non-biosynthetic) Env was quantified by combining both the internalized  
437 pool and surface Env values. As a control to establish whether AP-2-dependent  
438 internalization machinery was functional, the cell media were supplemented during the  
439 short anti-gp120 pulse with fluorescent transferrin (Tfn) to label the endosomal  
440 compartments (78, 79) (Fig. 10A – uninfected conditions). Tfn was internalized in both  
441 SupT1 and MT-4, confirming that both cell lines have an intact endocytosis machinery.  
442

443 To determine whether differences exist in Env internalization in SupT1 and MT-4, the  
444 ratio of surface to internalized Env was analyzed (Fig. 10B-C). Consistent with the flow  
445 cytometric analysis (Fig. 9), MT-4 expressed higher levels of total and surface Env than  
446 SupT1 (Fig. 10B). Surface Env expression on MT-4 was further increased by truncating  
447 the gp41 CT. To gain further insight into the ability of MT-4 to internalize Env, we  
448 determined the percent Env internalization during the pulse-chase (Fig. 10C). WT Env  
449 was internalized more rapidly in SupT1 than in MT-4. As expected, truncation of the  
450 gp41 CT resulted in less internalized Env for both MT-4 and SupT1. Altogether, the data  
451 suggest that Env levels on the surface of MT-4 cells may be higher than on other lines  
452 due to slower internalization.  
453

#### 454 *MT-4 serve as better targets for C-C transmission than the other cell lines tested.*

455 The results presented above suggest that levels of virion-associated Env and cell-free  
456 particle infectivity do not account for the permissivity of MT-4 cells to CT-truncated Env.  
457 We therefore explored the role of C-C transmission in the gp41 CT-truncation  
458 permissive phenotype. To gain a better understanding of MT-4 cells as a target for HIV-  
459 1 infection, we compared the relative ability of cell lines in the T-cell panel to be infected  
460 via C-C transmission, using 293T cells as the donor. Non-lymphoid 293T cells do not  
461 express the adhesion molecules LFA-1, ICAM-1, or ICAM-3 (80). Using 293T cells as  
462 the virus-producing donor cell enabled the study of viral transmission independent of  
463 differences in LFA-1:ICAM1/3 engagement, surface Env levels, and kinetics of HIV  
464 release, as C-C transfer in this system is dependent primarily on Env-CD4 interactions.  
465 Because ~50% of our Jurkat E6.1 cells do not express CD4 (Fig. 5A), this cell line was  
466 excluded from the analysis as the CD4<sup>-</sup> cells would not become infected in the assay.  
467 The vector used in this analysis encodes eGFP under control of the HIV-1 LTR; eGFP  
468 therefore labels cells infected by either the cell-free or C-C route. 293T were transiently  
469 transfected with an HIV-1 proviral clone encoding eGFP and 24 hours later either co-  
470 cultured with dye-labelled T cells or overlaid with a transwell containing dye-labelled T  
471 cells. Viral transfer in the co-culture thus represents the summation of both cell-free and  
472 C-C infection events (Fig. 11A). Evaluation of the transwell data showed that cell-free  
473 infection of MT-4 is less efficient relative to C8166 and M8166, but more efficient than  
474 SupT1 (Fig. 11B). Subtracting the transwell from the co-culture values produced the C-  
475 C contribution (Fig. 11C). The results indicated that MT-4 cells were more efficiently  
476 infected by C-C transmission than SupT1 or C8166. High MT-4 and M8166

477 susceptibility as target cells is not due to higher CD4 expression, since we found that  
478 SupT1 express higher levels of CD4 compared to either MT-4 or M8166 (Fig. 5A) and  
479 equivalent or greater levels of CXCR4 than MT-4 or M8166, respectively (Fig. 5B). The  
480 differences in susceptibility to C-C transmission from 293T donor to MT-4 and M8166  
481 targets were not statistically significant, suggesting that high susceptibility to C-C  
482 transmission likely contributes to, but does not entirely account for, the CT-truncation  
483 permissive phenotype of MT-4.

## 484 Discussion

485  
486 It has been previously reported in a number of studies that the CTdel144 gp41  
487 truncation mutant is unable to establish a spreading infection in most T-cell lines or  
488 primary hPBMCs. In this study, we sought to elucidate the basis for the unusual, and in  
489 our analysis unique, permissivity of the MT-4 T-cell line to truncation of the gp41 CT. To  
490 this end, a panel of validated T-cell lines known or reported to be permissive or non-  
491 permissive to gp41 CT truncation was compared to MT-4. We confirmed that the MT-4  
492 T-cell line is permissive to CT-truncation, but observed that other HTLV-transformed T-  
493 cell lines previously reported as permissive (14, 58, 81) are not. Differences in  
494 methodology or cell line origin likely explain the contrast in these findings. In part  
495 because of these differences, we extensively validated the T-cell lines used in the study.  
496 We found that HTLV-I Tax expression, viral entry efficiency, cellular levels of viral  
497 protein expression, virion-associated Env content, and cell-free viral infectivity did not  
498 solely account for permissivity to gp41 CT truncation. A combination of rapid HIV-1  
499 gene expression, enhanced cell-surface Env expression, and high susceptibility to C-C  
500 transmission compared to the non-permissive lines tested in this study likely explains  
501 the ability of MT-4 to overcome the requirement for the gp41 CT.

502  
503 It was previously suggested that MT-4 express higher levels of Gag proteins after HIV-1  
504 infection relative to the non-permissive cells examined (14). We found that in MT-4  
505 cultures, more cells were eGFP<sup>+</sup> over time indicating faster HIV-1 protein production  
506 kinetics compared to non-permissive cells. HTLV-I Tax expression and upregulated NF-  
507  $\kappa$ B activity were not associated with greater HIV-1 protein production; C8166 and  
508 M8166 expressed comparable levels of eGFP per cell relative to Tax<sup>-</sup> SupT1 and Jurkat  
509 E6.1. These contrasting results are likely explained by methodological differences; our  
510 flow cytometry approach allowed us to quantify both eGFP expression per cell, and  
511 number of cells expressing eGFP, at various time points, while the western blot  
512 approach used by Emerson et al. (14) measured total HIV-1 Gag expression in the cell  
513 cultures at a single time point. Both our study and that of Emerson et al. found that MT-  
514 4 cells release approximately 3-fold more virus than non-permissive cells. We conclude  
515 that this is due to faster kinetics of HIV-1 protein production in MT-4 cells rather than  
516 more protein being expressed per infected cell, relative to non-permissive cells.

517  
518 A recent report found that MT-4 and C8166 are likely permissive to type I IN mutations  
519 due to HTLV-I Tax expression inducing NF- $\kappa$ B protein recruitment to the HIV-1 LTR on  
520 unintegrated HIV-1 DNA (46). If this phenomenon were the cause of T-cell line  
521 permissivity to truncation of the gp41 CT, Tax<sup>+</sup> C8166 and M8166 would also be  
522 permissive to gp41 CT truncation. Furthermore, we found that MT-4, C8166, and M8166  
523 all display higher NF- $\kappa$ B activity compared to SupT1, indicating that they are all in a  
524 hyper-NF- $\kappa$ B activated state. Therefore, while Tax expression was found to overcome  
525 type I IN defects and activate transcription of non-integrated HIV-1 DNA in C8166 and  
526 MT-4 (46), this phenomenon does not account for the unique ability of MT-4 to host  
527 multiple rounds of CTdel144 infection.

528

529 Reduced Env incorporation in MT-4 was associated with a commensurate reduction in  
530 cell-free infectivity, suggesting that viral particles produced by MT-4 are inherently less  
531 infectious than those produced by non-permissive cells. We also observed that MT-4  
532 cells exhibit a higher level of Gag processing relative to SupT1 and a lower level of Env  
533 processing. More efficient Gag processing may be a consequence of increased  
534 assembly kinetics. Previous work has led to the hypothesis that the timing of Gag  
535 assembly versus Env expression on the surface can influence the efficiency of Env  
536 incorporation; a delay in Env trafficking to the surface relative to completion of Gag  
537 assembly reduces the efficiency of Env trapping by the nascent Gag lattice (19), a  
538 phenomenon that could account for the relatively inefficient Env incorporation observed  
539 in MT-4 relative to SupT1.

540  
541 Consistent with the role of the gp41 CT in regulating Env internalization from the PM,  
542 truncation of the gp41 CT resulted in enhanced surface Env expression on all T-cell  
543 lines tested (with the exception of M8166 in which the increase was not statistically  
544 significant) as observed in previous studies (17, 82, 83). Analysis of Env internalization,  
545 using a pulse-chase assay, found that the rate of Env internalization was reduced in  
546 MT-4 compared to SupT1. This reduced Env internalization may contribute to the  
547 reduced Env incorporation seen in MT-4, consistent with a role for gp41 CT-dependent  
548 internalization from the PM in Env incorporation during viral assembly (15-17). This  
549 finding suggests a recycling-independent Env incorporation model in MT-4, wherein the  
550 presence of a full-length tail allows for some enhancement of WT Env incorporation by  
551 Gag lattice trapping during particle assembly (22), compared to the passive, less  
552 efficient incorporation of the gp41 CT-truncated mutant which is unable to be trapped.  
553 The higher surface expression of Env in MT-4 cells contributes to the smaller effect of  
554 CT truncation in Env incorporation in MT-4 relative to non-permissive T-cell lines. This is  
555 consistent with the observation that in HeLa cells the Env incorporation defect observed  
556 with CTdel144 could be overcome by increasing Env expression (15); more Env on the  
557 surface leads to an increase in non-specific (passive) incorporation that is less  
558 dependent on the gp41 CT and its trapping by the Gag lattice (1). The higher surface  
559 expression of Env in MT-4 relative to non-permissive T-cell lines may also contribute to  
560 the formation of VSs and more productive transfer of CTdel144, which is more  
561 fusogenic than Env with a full-length CT (18), by C-C transmission.

562  
563 Our approach of using 293T as virus-donor cells allowed us to test the susceptibility of  
564 the T-cell line panel to infection by either cell-free or C-C transmission independent of  
565 the ability of the T-cell lines to serve as donor cells. We observed an approximately 3-  
566 fold higher susceptibility of MT-4 and M8166 cells to C-C transmission from 293T  
567 donors compared to SupT1 and C8166. These data indicate that a differential  
568 susceptibility to C-C transmission between C8166 and M8166 (a subclone of C8166  
569 more susceptible to formation of syncytia) arose during the generation of M8166.  
570 Because the lipid composition of the target cell membrane has been shown to affect  
571 viral fusion and entry (84, 85), it is possible that differences in PM lipid composition  
572 between the cell lines studied here account for the high susceptibility of MT-4 and  
573 M8166 to C-C transmission. Further studies will be required to evaluate this possibility.

574

575 This study reveals that multiple factors are associated with the ability of the MT-4 T-cell  
576 line to support the replication of a gp41 CT truncation mutant. The requirement for the  
577 gp41 CT in MT-4 is likely overcome by the additive effects of rapid HIV-1 protein  
578 production, high levels of cell-surface Env expression, and increased susceptibility to C-  
579 C transmission compared to non-permissive cells. These results highlight that Env  
580 incorporation, viral transfer, and ultimately the establishment of a spreading infection  
581 are influenced by a number of factors including the kinetics of viral protein expression  
582 and virus assembly, the levels of Env expressed on the cell surface, and the rate of Env  
583 trafficking and internalization.  
584



## 585 **Materials & Methods**

586

### 587 Cell lines and culture

588 293T [obtained from American Type Culture Collection (ATCC)] and TZM-bl [obtained  
589 from J. C. Kappes, X. Wu, and Tranzyme, Inc. through the NIH AIDS Reagent Program  
590 (ARP), Germantown, MD] cell lines were maintained in DMEM containing 5% or 10%  
591 (vol/vol) fetal bovine serum (FBS), 2 mM glutamine, 100 U/mL penicillin, and 100 µg/mL  
592 streptomycin (Gibco) at 37 °C with 5% CO<sub>2</sub>. Jurkat E6.1, MT-4, C8166-45 (referred to  
593 as C8166), and M8166 were obtained from Arthur Weiss (Cat# 177), Douglas Richman  
594 (Cat# 120), Robert Gallo (Cat# 404), and Paul Clapham (Cat# 11395), respectively,  
595 through the NIH ARP. The source of SupT1 used in this study is unknown. The SupT1-  
596 CCR5 (86) T-cell line was a generous gift from James Hoxie. The ATL Tax<sup>-</sup> cells lines  
597 (ED, ATL-35T, and TL-Om1) were a generous gift from Chou-Zen Giam. T-cell lines  
598 were maintained in RPMI-1640 medium containing 10% FBS, 2 mM glutamine, 100  
599 U/mL penicillin, and 100 µg/mL streptomycin (Gibco) at 37 °C with 5% CO<sub>2</sub>. Whole  
600 blood was obtained from healthy donors via the NIH Clinical Center. hPBMCs were  
601 isolated using a ficoll gradient and stimulated with 2 µg/mL PHA-P for 3 – 5 days before  
602 infection, then cultured in 50 U/mL IL-2.

603

### 604 Cloning and plasmids

605 The HIV-1 pNL43-nef<sup>-</sup>-eGFP reporter vector (also called pBR43leGFP-nef<sup>-</sup>; Cat#  
606 11351) [obtained through the NIH ARP from Frank Kirchhoff]. The Env<sup>-</sup> construct was  
607 generated by restriction digest of the pNL4-3/KFS clone (87), referred to here as pNL4-  
608 3 Env<sup>-</sup>, and target vector with *Stu*I and *Xho*I restriction enzymes followed by ligation of  
609 the Env fragment into pBR43leGFP-nef<sup>-</sup> to generate pBR43leGFP-nef<sup>-</sup>Env<sup>-</sup>. Unless  
610 otherwise indicated, the full-length HIV-1 clade B molecular clone pNL4-3 was used  
611 (88). The Env<sup>-</sup> (87) and CTdel144 clone (26) were described previously. Wild-type and  
612 CTdel SIVmac239 were generated by Bruce Crise and Yuan Li and were a generous  
613 gift from Jeff Lifson. Plasmid sequences were confirmed by restriction digest with *Hind*III  
614 and Sanger sequencing. The HIV-1 YU2 Vpr β-lactamase expression vector (pMM310)  
615 was [obtained from Michael Miller, Cat # 11444, through the NIH ARP]. The plasmids  
616 pHR'CMV-GFP and pHR'CMV-Tax were a generous gift from Chou-Zen Giam.

617

618 For confocal microscopy, non-propagating, release-defective constructs were generated  
619 (pSVNL4-3-ctfl-dPol-dVV-GFP-3'LTR and pSVNL4-3-ctfl-dPol-dVV-dCT-GFP-3'LTR  
620 where ctfl = C-terminal FLAG tag on Gag, dPol = deletion of Pol, dVV = deletion of Vif  
621 and Vpr, by removal of the *Afl*III fragment, GFP = green fluorescent protein in place of  
622 Nef). Expression plasmids for Env and associated mutants in addition to Gag were  
623 natively expressed from the reference HIV-1 clone NL4-3 with the following  
624 modifications: the pNL4-3 vector was sub-cloned into an SV40 ori-containing backbone  
625 (pN1 vector; Clontech; pSVNL4-3), deletion of *pol* by removal of the *Bcl*I-*Nsi*I fragment,  
626 mutation of the p6 PTAP motif (455PTAP458-LIRL) (89), addition of a coding C-terminal  
627 FLAG tag to the Gag open reading frame to detect Gag expression (GSDPSSQ500-  
628 SGDYKDDDDK) (90) and removal of the 5' portion of the *nef* open reading frame and  
629 replacement with a GFP coding sequence.

630

631 Preparation of virus stocks.

632 293T cells were transfected with HIV-1 proviral DNA using Lipofectamine 2000  
633 (Invitrogen) according to the manufacturer's instructions. Virus-containing supernatants  
634 were filtered through a 0.45- $\mu$ m membrane 48 h post-transfection and virus was  
635 quantified by measuring RT activity. VSV-G-pseudotyped virus stocks were generated  
636 from 293T cells co-transfected with proviral DNA and the VSV-G expression vector  
637 pHCMV-G (91) at a DNA ratio of 10:1.

638  
639 For confocal microscopy, virus particles were made using the pSVNL4-3 plasmids.  
640 Briefly, VSV-G-pseudotyped, single-round viruses were produced by transfecting 293T  
641 cells with the pSVNL4-3 plasmids, the psPAX2 packaging plasmid (a gift from Didier  
642 Trono, Addgene plasmid #12260), and pVSV-G expression plasmid using PEI  
643 transfection reagent (Alfa Aesar/Thermo Fisher Scientific). The virus was harvested at  
644 ~48 hours after transfection and stored at -80 °C.

645  
646 STR profiling and cell line validation

647 The identity of cells in the T-cell line panel was confirmed by performing STR profiling  
648 as described previously (43). Briefly, genomic DNA was extracted and sent to Genetica  
649 (LabCorp) for profiling. The URL for this data set is:  
650 [https://amp.pharm.mssm.edu/Harmonizome/gene\\_set/IRF3/ENCODE+Transcription+Fa](https://amp.pharm.mssm.edu/Harmonizome/gene_set/IRF3/ENCODE+Transcription+Factor+Targets)  
651 [ctor+Targets](https://amp.pharm.mssm.edu/Harmonizome/gene_set/IRF3/ENCODE+Transcription+Factor+Targets). The obtained STR profile was compared to the Cellosaurus reference  
652 STR using the % Match formula (92).

653  
654 Illumina RNA-Seq

655 RNA was extracted from T cells in their exponential growth phase using QIAshredder  
656 (Qiagen, Cat# 79654) and RNeasy Plus Mini Kit (Qiagen, Cat# 74134). RNA sample  
657 integrity was assessed by determining the RNA Integrity Number (RIN) with an Agilent  
658 2100 Bioanalyzer instrument and applying the Eukaryote Total RNA Nano assay. RIN  
659 values were between 9 and 10, indicating intact RNA. Samples were sequenced on a  
660 HiSeq 2500, generating an average of 50 million raw reads per sample. Transcript  
661 sequence reads were normalized against the total reads for each cell line to generate a  
662 reads per kilobase per million mapped reads (RPKM) value. The RPKM is a relative  
663 measure of transcript abundance.

664  
665 A panel of NF- $\kappa$ B-dependent genes was obtained by random selection of genes from a  
666 database of NF- $\kappa$ B target genes (70). An IRF3-dependent gene panel was obtained  
667 from the Harmonizome search engine (71) by searching the ENCODE Transcription  
668 Factors gene set titled "IRF3" (72). This gene set contains 4159 IRF3 transcription  
669 factor target genes obtained from DNA-binding by ChIP-seq datasets. Genes dually  
670 targeted by NF- $\kappa$ B and IRF3 were removed from the IRF3-dependent gene panel used  
671 in our analysis.

672  
673 To analyze expression of NF- $\kappa$ B and IRF3 target genes, the average RPKM for each  
674 parent gene transcript was mined from the total acquired RNA-seq data set. RPKM  
675 values of zero were set to 1 to allow for fold-change analysis. HTLV-transformed cell

676 lines were compared to the lymphoma-derived SupT1 line to generate the fold-change  
677 value. This value was then converted by Log2 transformation.

678

### 679 Virus Replication Assays

680 Virus replication kinetics were determined in Jurkat E6.1 and MT-4 cell lines as  
681 previously described (26). Briefly, T cells were transfected with proviral clones (1 µg  
682 DNA/10<sup>6</sup> cells) in the presence of 700 µg/ml DEAE-dextran. MT-4, C8166, and M8166  
683 cells were split 1:2 every 2 days, and SupT1 and Jurkat E6.1 were split 1:3 every 2-3  
684 days with fresh media. VSV-G-pseudotyped virus was used to inoculate stimulated  
685 hPBMCs. Virus stocks were normalized by <sup>32</sup>P RT activity and used to initiate spreading  
686 infection. After a 2-hour incubation with VSV-G-pseudotyped virus, cells were washed  
687 and resuspended in fresh RPMI-10% FBS. Every other day half the medium was  
688 replaced without disturbing the cells. Virus replication was monitored by measuring the  
689 RT activity in collected supernatants over time. RT activity values were plotted using  
690 GraphPad Prism to generate replication curves.

691

### 692 HIV-1 infection of T cells

693 293T cells were plated and co-transfected via lipofectamine the next day with the pNL4-  
694 3 proviral clone and the VSV-G expression vector, pHCMV-VSV-G, at a 10:1 ratio. 48  
695 hours post-transfection, supernatants were passed through a 0.45 µm filter and RT  
696 activity was measured by <sup>32</sup>P RT activity assay as described (93). T cells were plated  
697 the night before infection in fresh media at a density of 5x10<sup>6</sup> cells / 2 mL. The following  
698 day, cells were infected overnight with RT-normalized virus.

699

### 700 Western blotting for viral proteins

701 The morning after transduction, cells were washed extensively to remove any  
702 unabsorbed virus, and plated in 1.5 mL of RPMI-10. 42 hours post-infection, cells were  
703 pelleted and lysed. Virus-containing supernatants were passed through a 0.45µm filter.  
704 10 µL were set aside for RT assay and 200 µL were set aside for TZM-bl infectivity  
705 assay. The remaining filtered virus-containing supernatant was layered on a 20% w/v  
706 sucrose/phosphate buffered saline (PBS) solution and spun for 1.25 h at 41,500 x g at  
707 4°C in a Sorvall S55-A2 fixed angle rotor (ThermoFisher Scientific). Cell and virus  
708 fractions were lysed in lysis buffer (30 mM NaCl, 50 mM Tris-HCL pH 7.5, 0.5 % Triton  
709 X-100, 10mM Iodoacetamide, complete protease inhibitor (Roche)). Lysates boiled with  
710 6x loading buffer (7 mL 0.5 M Tris-HCL/0.4 % SDS, 3.8 g glycerol, 1 g SDS, 0.93 g  
711 DTT, 1.2 mg bromophenol blue) were subjected to SDS-PAGE on 12% 1.5 mm gels  
712 and processed using standard western blotting techniques. All antibodies were diluted  
713 in 10 mL of 5% milk in TBS blocking buffer. HIV proteins were detected with 10 µg/mL  
714 polyclonal HIV immunoglobulin (HIV-Ig) obtained from the NIH ARP. Anti-human IgG  
715 conjugated to horseradish peroxidase (HRP) was obtained from SigmaAldrich (Cat#  
716 GENA933) and used at a 1:5000 dilution. gp41 was detected with 2 µg/mL10E8  
717 monoclonal antibody obtained from the NIH ARP (Cat# 12294) followed by anti-human  
718 IgG-HRP as above.

719

720 To detect HTLV-I Tax protein, 2x10<sup>6</sup> cells were lysed in 100 µL of lysis buffer and 30 µL  
721 of 6x loading buffer and boiled for 10 min. 20 µL of cell lysates were loaded on a 12%

722 1.5mm Tris-glycine gel and processed using standard western blotting techniques.  
723 HTLV-I Tax was detected with an anti-Tax-1 mouse monoclonal (Abcam, Cat#  
724 ab26997) at a 2 µg/mL concentration followed by goat-anti-mouse-HRP antibody  
725 (Thermo Fisher, Cat # 32230) at a 0.5 µg/mL concentration. β-actin was used as a  
726 loading control and detected using anti-β-actin conjugated directly to HRP (Abcam, Cat#  
727 ab49900). Protein bands were visualized using chemiluminescence with a Bio-Rad  
728 Universal Hood II ChemiDoc and then analyzed with ImageLab v5.1 software or the  
729 Azure Spot Analysis Software.

730  
731 Metabolic labeling and radioimmunoprecipitation were performed as previously  
732 described (21). Phosphor screens were imaged with a Bio-Rad Personal Molecular  
733 Imager System and quantitative analysis of bands was performed with the Azure Spot  
734 Analysis Software.

735  
736 Viral entry assay  
737 BlaM-Vpr-containing viruses were produced by transient co-transfection of 239T cells  
738 with pNL4-3 constructs encoding either Env<sup>-</sup>, WT, or CTdel144 sequences, a second  
739 plasmid (pMM310 – NIH ARP Cat# 11444) encoding the BlaM-Vpr fusion protein, and a  
740 third plasmid (pAdvantage - Promega, Cat# E1711) to enhance transient protein  
741 expression at a 6:2:1 ratio. For the VSV-G control, pHCMV-VSV-G was provided in  
742 *trans* at a 10:1 ratio relative to pNL4-3. Virus-containing supernatant was filtered 48  
743 hours post-transfection and concentrated using Lenti-X concentrator (TakaraBio, Cat#  
744 631231) according to the manufacturer's instructions. After concentration, the virus  
745 particles were resuspended in CO<sub>2</sub>-independent media (ThermoFisher, Cat#  
746 18045088), aliquoted, and stored at -80°C. Resuspended virus was diluted 10,000x and  
747 virus concentration was measured using two methods: (1) p24<sup>gag</sup> concentration by  
748 Lenti-X GoStix Plus (TakaraBio, Cat# 631280) and (2) <sup>32</sup>P RT activity (93).

749  
750 Entry of BlaM-Vpr-containing virus was detected using a fluorescent substrate, CCF2-  
751 AM (Thermo Fisher, Cat# K1032) (94). To perform the BlaM-Vpr assay, a suspension of  
752 20x10<sup>6</sup> cells/mL was made. 100 µL of this suspension was aliquoted per well of a U-  
753 bottom plate. Cells were infected for 4 h at 37°C with 400 ng p24<sup>gag</sup>. After incubation  
754 with virus, cells were washed 2x with CO<sub>2</sub>-independent media supplemented with 10%  
755 FBS. Cells were then resuspended in 100 µL CO<sub>2</sub> independent media with 10% FBS  
756 and 20 µL of the CCF2-AM reagent (prepared according to the manufacturer's  
757 instructions). Cells were incubated for 1 hour with the CCF2-AM reagent in darkness at  
758 room temperature. Cells were then washed 2x with PBS, resuspended in CO<sub>2</sub>-  
759 independent media + 10 % FBS and left at room temperature in darkness overnight.  
760 Sixteen hours later, cells were fixed in 100 µL 4% PFA and analyzed the same day.  
761 Flow cytometric analysis utilized a Fortessa X-20 flow cytometer (BD Bioscience) and  
762 FlowJo software (Tree Star Inc, Ashland, OR, USA).

763  
764 Single-cycle infectivity assays  
765 TZM-bl infectivity assays were performed as previously described (95). Briefly, 20,000  
766 TZM-bl cells were plated in a flat-bottomed white-walled plate (Sigma Aldrich, Cat#  
767 CLS3903-100EA). The following day, the cells were infected with serial dilutions of RT-

768 normalized virus stocks in the presence of 10 µg/mL DEAE-dextran. Approximately 36  
769 hours post-infection, cells were lysed with BriteLite luciferase reagent (Perkin-Elmer)  
770 and luciferase was measured in a Wallac BetaMax plate reader.

771

### 772 Flow cytometry

773 Cells were resuspended in 8% BSA/PBS at a concentration of  $10^7$  cells/mL. 100 µL was  
774 aliquoted into a 96-well V-bottom plate (SigmaAldrich, Cat# CLS3897). An antibody  
775 solution was made using 20 µL of either isotype or target antibody per test, as  
776 recommended by the manufacturer. The following antibodies from BD Pharmigen were  
777 used: APC mouse IgG2a κ isotype control (Ca# 555576), APC mouse anti-CD184  
778 (CXCR4) (Cat# 560936), PE mouse anti-CD4 (Cat # 555347). The isotype control for  
779 CD4 was acquired from Biolegend (PE mouse IgG1, κ isotype control, Cat# 400113).  
780 Cells were incubated with antibodies for 20 min at room temperature, then washed 3x  
781 with PBS. Samples were analyzed via the BD FACSCalibur flow cytometer (BD  
782 Bioscience) and FlowJo software (Tree Star Inc.).

783

784 To detect cell-surface Env, infected cells were washed with PBS and fixed with 4% PFA  
785 overnight at 4°C. The following day, the PFA was quenched with 0.3 M glycine in PBS  
786 using three rounds of 5 min incubations. Cells were then resuspended in 100 µL of 8%  
787 BSA/PBS. An antibody cocktail was made by diluting b12 and 2G12 in 8% BSA/PBS  
788 [obtained from Dr. Dennis Burton and Carlos Barbas, and Polymun Scientific,  
789 respectively, via the NIH-ARP] and aliquoting 100 µL to each sample to obtain a final  
790 concentration of 2 µg/mL of both antibodies. The cell:antibody mixture was incubated at  
791 room temperature for 20 min. Unbound antibody was removed with three PBS washes.  
792 Goat anti-human conjugated to Alexa Fluor 488 was used as a secondary antibody  
793 (Invitrogen, Cat# A11013) at a concentration of 2 µg/mL. Cells were incubated with  
794 secondary antibody for 20 min at room temperature and washed 3x with PBS before  
795 analysis on the BD FACSCalibur.

796

### 797 C-C transmission assay

798 293T were transfected with pBR43leGFP-nef<sup>+</sup> (Cat# 11349; NIH ARP) or an Env<sup>-</sup>  
799 derivative (described above). 24 hours post-transfection, dye-labelled T cells were  
800 added to the transfected 293T cells at a 4:1 ratio in either a co-culture or to the top layer  
801 of a transwell. 12 hours post-coculture, BMS-806 was supplemented into the media at a  
802 concentration of 2000 nM to prevent the formation of syncytia and T cell to T cell  
803 transmission. Forty-eight hours post-coculture, cells were fixed in 4% PFA and analyzed  
804 by flow cytometry. Data were collected via CellQuest and processed with FlowJo  
805 software (Tree Star Inc).

806

### 807 Production of anti-Env monovalent Fab b12-Atto565 probe

808 The anti-Env b12 Fab recombinant expression vector was a kind gift from  
809 Dennis Burton (96). A 4x lysine tag, to enhance dye conjugation efficiency (97), was  
810 added to the C-terminus of the b12 light chain using site-directed mutagenesis.  
811 Expression of b12 was carried out as previously described (19, 98). Briefly, clarified cell  
812 lysates were purified by protein G affinity chromatography (Gold Biotechnology, Inc.).  
813 The b12 Fab, typically 99% pure, was conjugated with Atto565 N-hydroxysuccinimidyl

814 ester (Sigma-Aldrich). Typically, a labeling ratio of 1 Atto565 dye molecule per b12 Fab  
815 molecule was achieved.

816

### 817 Pulse-chase staining

818 For each sample,  $6-8 \times 10^5$  MT-4 or SupT1 cells were transduced with VSV-G-  
819 pseudotyped virus encoding either WT or CTdel144 Env (described above).  
820 Approximately 40 hours post-infection, the cells were blocked with 10% BSA in  
821 complete media for 30 min at 37°C with 5% CO<sub>2</sub>, stained with custom Fab b12-Atto565  
822 (25 nM) and Transferrin-AlexaFluor647 (Transferrin-AF647; Invitrogen; 25 µg/mL) in  
823 media with 6% BSA, and washed thrice for 5 min with the same media. The cells were  
824 then placed onto 18 mm coverslips pre-treated with poly-L-lysine (Ted Pella Inc.), fixed  
825 with 4% and 0.2% paraformaldehyde and glutaraldehyde in PBS, respectively.  
826 Coverslips were then mounted onto glass slides with Fluoromount-G (Southern  
827 Biotech).

828

### 829 Microscopy

830 Imaging of the cellular specimens was performed with a spinning-disk confocal  
831 microscope built on an inverted Nikon Ti-E base (Solamere Technology Group Inc., Salt  
832 Lake City, UT) using a 60x, CFI Plan Apo Lambda 1.4 NA oil-immersion objective  
833 (Nikon Instruments). Fiber-coupled lasers (OBIS, Coherent) were used with a CSU-X  
834 A1 spinning disk unit (Yokogawa Electronics) to excite and collect confocal fluorescence  
835 sections. Transferrin-AF647 was imaged using a 640 nm laser at 12 mW with 40 ms  
836 exposure, Atto565 was imaged using a 561 nm laser at 24 mW with 100 ms exposure,  
837 and GFP was imaged using a 488 nm laser at 12 mW with 40 ms exposure. Laser  
838 power was measured at the specimen. Z-stacks for each field of view were collected at  
839 0.3 µm spacing.

840

### 841 Image analysis

842 Quantitation of surface-exposed and internalized Env signal in the pulse-chase assay  
843 images was performed using ImageJ software. First, for each z-stack, a maximum  
844 intensity projection was generated for a 4.5 µm range through the middle of the cells.  
845 The background was subtracted using ImageJ's built-in "rolling ball" background  
846 subtraction process with a radius of 150 pixels. Cells were excluded from analysis if  
847 they did not express GFP (non-infected cells) or did not internalize transferrin (dead or  
848 dysfunctional cells), or if the maximum intensity projection did not represent an  
849 equatorial section of the whole cell. Integrated intensity was then estimated using two  
850 regions of interest (ROIs) in the Atto565 channel: (1) an outer ROI was manually  
851 segmented to enclose the entire cell, including any plasma-membrane-associated  
852 signal, and (2) an interior ROI was manually segmented just inside the PM, excluding  
853 any PM-associated signal. Signal for Env on the PM was thus enclosed between these  
854 two ROIs, and signal for the internalized Env pool was enclosed within the interior ROI.  
855 The integrated intensity of the outer ROI (1) minus that of the inner ROI (2) served as a  
856 measure of surface-exposed Env, while the integrated intensity of the inner ROI (2)  
857 served as a measure of internalized Env.

858

### 859 Statistics

860 Statistics were calculated using GraphPad Prism version 8 for Mac OS (GraphPad  
861 Software, La Jolla, CA). Unpaired Student's t-tests were performed and two-tailed \*P <  
862 0.05, \*\*P < 0.01, \*\*\*P < 0.001, and \*\*\*\*P < 0.0001 were considered statistically  
863 significant. GraphPad Prism was also used to calculate standard error and to assess  
864 statistical significance by one-way ANOVA. P values for Student's t-test and one-way  
865 ANOVA analysis are defined with the same cut-offs.

866

867 *Ethics Statement*

868 PBMCs were obtained from anonymous, de-identified blood donors to the NIH  
869 Department of Transfusion Medicine Blood Products Program (NIH CC-DTM).

870

871 **List of abbreviations.**  
872 CT – cytoplasmic tail  
873 VS – virological synapse  
874 C-C – cell-to-cell  
875 Env – envelope glycoprotein  
876 STR – short tandem repeat  
877 MFI – median fluorescence intensity  
878 PM – plasma membrane  
879 Radio-IP – radio-immunoprecipitation  
880 hPBMC – human peripheral blood mononuclear cells  
881 RT –reverse transcriptase  
882 VSV-G – Vesicular stomatitis virus glycoprotein  
883 PBS – phosphate buffered saline  
884 FBS – fetal bovine serum  
885 WT – wild type  
886 HRP – horseradish peroxidase  
887 ER – endoplasmic reticulum  
888 MA – HIV-1 Matrix protein  
889 EBV – Epstein-Barr virus  
890 HTLV – Human T-cell leukemia virus  
891 ALL – Acute lymphocytic leukemia  
892 ATL – Adult T-cell lymphoma  
893 ATCC – American Type Culture Collection  
894 NIH ARP – NIH AIDS Reagent Program  
895 n.s. – not statistically significant  
896 IN – HIV-1 Integrase protein  
897 CA – HIV-1 Capsid protein  
898 RIN - RNA Integrity Number  
899



900 **Declarations.**

901 *Competing interests.*

902 The authors declare that they have no competing interests.

903

904 *Authors' contributions*

905 MVF and EOF designed the study. MVF and HKH performed the experiments and  
906 analysis, and NP generated the fluorescently labelled b12 monovalent Fab for the  
907 microscopic analysis. PT performed initial western blots comparing Env content in  
908 virions produced in SupT1 and MT-4. SBvE contributed valuable feedback and  
909 guidance on the microscopy experiments. All authors made contributions to writing the  
910 manuscript.

911

912 *Acknowledgements*

913 We thank members of the Freed and van Engelenberg labs for helpful discussion and  
914 for critical review of the manuscript. We thank James Hoxie for providing the SupT1-  
915 CCR5 cell line, Erin M. Hall at Genetica (Lab Corp) for assistance with STR profiling  
916 and data interpretation, Douglas Richman for providing historical information on the  
917 treatment of MT-4 cells prior to donation to the NIH ARP, and James A. Thomas for  
918 assisting with the BlaM-Vpr flow cytometry acquisition. We thank Chou-Zen Giam for  
919 helpful discussion and for providing the ATL Tax<sup>-</sup> T-cells (ED, ATL-55T, and TL-Om1)  
920 and expression vectors for Tax and GFP expression. We also thank Yongmei Zhao at  
921 the NCI-Center for Cancer Research Sequencing Facility for performing the Illumina  
922 RNA-seq and assisting with the differential RNA analysis. This study was supported by  
923 the Intramural Research Program of the Center for Cancer Research, National Cancer  
924 Institute, NIH and by an Intramural AIDS Research Fellowship (for MVF).

925

926 **Figure Legends.**

927

928 Figure 1. Lineage of cell lines used to interrogate T-cell line permissivity to replication of  
929 an HIV-1 mutant lacking the gp41 CT.

930 A) The SupT1 T-cell line was derived from a pleural effusion of a male patient with non-  
931 Hodgkin's lymphoma. Cells were sub-cloned by limiting dilution to generate a cell line  
932 capable of continual growth from a single-cell colony (59). B) The peripheral blood of a  
933 14-year-old boy with relapsed acute lymphocytic leukemia (ALL) was used to generate  
934 the EBV<sup>-</sup>, IL-2-dependent JM T-cell line (60). The JM line was then subcloned to  
935 generate the Jurkat-FHCRC subclone for its ability to produce IL-2 upon stimulation with  
936 phorbol esters or lectins (99). "-FHCRC" designation indicates the cell line originated at  
937 the Fred Hutchinson Cancer Research Center. Jurkat-FHCRC was then subjected to  
938 limiting dilution to generate an IL-2 -independent, mycoplasma-free cell line, Jurkat E6.1  
939 (100). C) To generate the MT-4 cell line, cells from an adult male ATL patient were co-  
940 cultured with male human infant cord leukocytes, therefore it is unknown whether these  
941 cells are of cord leukocyte or ATL cell origin (61). Cells were gifted to the lab of Douglas  
942 Richman by Harada et al. (101) and serially passaged by terminal dilution cloning of the  
943 cells in the presence of ciprofloxacin until they were determined to be mycoplasma free.  
944 These cells were then donated to the NIH ARP by Douglas Richman (D. Richman,  
945 personal communication). D) To generate the C8166 T-cell line, cells were first acquired  
946 from a 26-year-old male ATL patient's inguinal lymph node (102) and maintained in IL-2  
947 for several passages until they were deemed IL-2 independent (103). This T-cell line,  
948 HUT 102, was determined to be EBV<sup>-</sup> and HTLV<sup>+</sup>. The CR-M2 subclone of HUT 102  
949 was then isolated and further purified by percoll gradient isolation to generate a cell line  
950 with increased HTLV production, designated CR<sub>II</sub> (104). CR<sub>II</sub> was then used to  
951 transform human umbilical cord blood T leukocytes by cell hybridization to generate the  
952 C63/CR<sub>II</sub>-2 cell line, also known as the C8166-45 (aka 81-66 or C8166) cell line (62).  
953 The "-45" designation indicates the cell line has 45 chromosomes. "CR" indicates the  
954 cells were transformed by the HTLV-I<sub>CR</sub> virus. Characterization of this line found that it  
955 produces HTLV-I RNA but no virus particles (62). C8166 were then subjected to limiting  
956 dilution to generate a clone more susceptible to formation of syncytia when cultures  
957 were infected with HIV-1 (105). This new C8166-derived cell line was named M8166.

958

959 Figure 2. Spreading infection kinetics of SIVmac239 in C8166 and M8166.

960 A) C8166 and B) M8166 were transfected with SIVmac239 encoding the indicated Env  
961 CT genotype. Supernatant was sampled every 2-3 days for analysis by HIV-1 RT assay  
962 and cell cultures were split 1/2. Data are representative of 3 independent experiments.

963

964 Figure 3. MT-4 is the only T-cell line tested that is permissive to the gp41 CT truncation  
965 mutant CTdel144.

966 A) Schematic representation of the NL4-3 gp41 CT and gp41 CT genotypes used in this  
967 study. The lentiviral lytic peptide (LLP) domains are indicated in grey boxes and the  
968 highly conserved tyrosine endocytosis motif is indicated with a shaded black rectangle.  
969 The CTdel144 mutant was generated by introducing two stop codons in the highly  
970 conserved tyrosine endocytosis motif, resulting in a CT of 4 amino acids (26). The  
971 numbers above the gp41 CT schematic indicate the first and last amino acid positions of

972 the gp41 CT. The number below the gp41 CT indicates the position of the QGYSP  
973 sequence. The tyrosine endocytosis motif, GYSPL, is underlined. (B-G) Replication  
974 curves for spreading infection are shown. B-F) Cell lines were either mock transfected  
975 or transfected with pNL4-3 encoding the indicated gp41 CT genotype. Cells were split  
976 B-D) 1/2 or E-F) 1/3 every 2-3 days, and an aliquot of the supernatant was reserved for  
977 analysis of HIV-1 RT activity at each time point. G) hPBMCs were transduced with VSV-  
978 G-pseudotyped NL4-3 encoding the indicated gp41 CT genotype or mock infected.  
979 Supernatant was sampled every 2-3 days for analysis of HIV-1 RT activity and cell  
980 cultures were supplemented with fresh media. Data are representative of 3 independent  
981 experiments (B-F) and 3 donors (G).

982  
983 Figure 4. *NF- $\kappa$ B-target gene expression in Tax-expressing T-cell lines is higher than in*  
984 *SupT1.*

985 A) Cell lysates from the indicated cell lines were analyzed by western blot for HTLV-I  
986 Tax expression. 293T were transfected with a GFP expression vector as a transfection  
987 control, or a Tax expression vector as a control for antibody specificity. ATL Tax-  
988 deficient cells were included as negative control for Tax expression in immortalized T-  
989 cell lines. B-D) RNA levels of the indicated NF- $\kappa$ B- and IRF3-target genes were  
990 compared to SupT1. RNA levels were determined by Illumina RNA-seq. As described in  
991 more detail in the methods, comparisons are reported as the Log<sub>2</sub> of the fold-change  
992 (FC) of the HTLV-transformed line (MT-4, C8166, or M8166) relative to the lymphoma-  
993 derived T-cell line, SupT1.

994  
995 Figure 5. *Viral entry mediated by full-length and CT-truncated Env is equivalent among*  
996 *HTLV-transformed T-cell lines.*

997 A) Surface CD4 and B) CXCR4 was measured by flow cytometry. MFI was determined  
998 by measuring the MFI value of CD4<sup>+</sup> or CXCR4<sup>+</sup> histograms and subtracting the isotype  
999 control MFI to directly compare MFIs between samples. To account for fluctuations in  
1000 flow cytometry data that occur when comparing data from different experiments, cells  
1001 from different acquisition dates were stained with antibody, fixed, and analyzed in  
1002 parallel by flow cytometry. The bar graphs show the mean MFI values of cell surface A)  
1003 CD4 and B) CXCR4,  $\pm$  SD from three independent experiments and the bar shading for  
1004 ease of comparison between panels A) and B). C) BlaM-Vpr-based viral entry assays  
1005 were performed using NL4-3 expressing either WT or CTdel144 Env. A mock treatment  
1006 and Env<sup>-</sup> NL4-3 pseudotyped with VSV-G were used as a positive control and Env<sup>-</sup> was  
1007 used as a negative control. Representative FACS dot plots are shown. Virus dose used  
1008 for each condition was titrated to avoid saturation (in the case of VSV-G and WT) and to  
1009 be above the Env<sup>-</sup> conditions (in the case of CTdel144). Therefore, values can only be  
1010 compared between cell lines for each condition, not between conditions. The bar graphs  
1011 show the fold change in viral entry relative to SupT1 (set at 1) between D) VSV-G-  
1012 pseudotyped Env<sup>-</sup> NL4-3, E) WT NL4-3, and F) CTdel144 NL4-3 with SD representing  
1013 comparison of values derived from three independent experiments. Statistical  
1014 significance was assessed by one-way ANOVA and Tukey's multiple comparison test.  
1015 P-values are defined in the Materials and Methods.

1016

1017 Figure 6. *Kinetics of virus release in MT-4 are faster than in other T-cell lines tested.*

1018 Cells were transduced with VSV-G-pseudotyped pBR43leGFP-nef<sup>-</sup>Env<sup>-</sup> reporter vector  
1019 and collected at various time points. A) The percent of cells expressing eGFP at each  
1020 time point was plotted. Error bars indicating the standard deviation of duplicate  
1021 infections are too small to be seen. B) Histogram of eGFP expression in the cell lines  
1022 48-hour post-transduction indicating the percent of cells expressing eGFP and their MFI  
1023 relative to an eGFP<sup>-</sup> control. C) eGFP levels at various time points post-transduction  
1024 (p.t.) were determined by the eGFP MFI from which the background MFI from the  
1025 eGFP<sup>-</sup> construct was subtracted. The bar graph shows the mean eGFP MFI,  $\pm$  SD from  
1026 three independent experiments. D) Cells lines were transduced with VSV-G-  
1027 pseudotyped NL4-3 Env<sup>-</sup>, washed, and supernatant HIV-1 RT activity was measured  
1028 42-hours post-transduction. The bar graph shows the mean fold-change relative to the  
1029 SupT1 reference line,  $\pm$  SD from three independent experiments. Statistical analysis  
1030 was performed to compare cell lines relative to SupT1 at individual time points post-  
1031 transduction or between two samples as indicated by the horizontal line between two  
1032 bars. n.s. indicates no statistical difference between the indicated cell line and the  
1033 SupT1 reference or between two samples as indicated by the horizontal line between  
1034 two bars. Statistical significance was assessed by one-way ANOVA and Tukey's  
1035 multiple comparison test.

1036

1037 **Figure 7. Env incorporation in MT-4 cells is inefficient.**

1038 SupT1 (A) and MT-4 (B) cells were transduced with RT-normalized VSV-G-  
1039 pseudotyped NL4-3 encoding either WT or CTdel144 Env. Cells were metabolically  
1040 labeled with [<sup>35</sup>S]Cys and cell and virus lysates were immunoprecipitated to detect HIV  
1041 proteins. The locations of p66(RT), the Gag precursor Pr55Gag, p32(IN), and p24(CA)  
1042 are indicated. Western blotting was performed on the virus fraction to detect gp41 and  
1043 p24(CA) using equal amounts of WT and CTdel144 viral lysates. gp41.t indicates the  
1044 position of the truncated gp41, CTdel144. The fold-change in Env incorporation  
1045 between WT and CTdel144 Env, calculated by determining the ratio of virion-associated  
1046 gp41 to p24(CA) relative to the WT condition, is indicated below the western blots. C)  
1047 SupT1 and MT-4 were transduced as in (A-B) and RT-normalized virus was used to  
1048 compare gp41 content in the virus fraction. Samples were analyzed by [<sup>35</sup>S]Cys radio-  
1049 immunoprecipitation (IP) and western blot (detected by chemiluminescence). The bar  
1050 graph shows the mean values relative to the SupT1 reference line,  $\pm$  SD from three  
1051 independent experiments. D) Env processing efficiency was quantified by dividing cell-  
1052 associated gp120 by the total cell-associated Env band intensity  
1053 [gp120/(gp120+gp160)]. E) The cell-associated Env-to-Gag ratio was determined as  
1054 [gp120/(Pr55Gag+p24)]. F) Gag processing was determined by dividing p24(CA) by  
1055 total Gag band intensity. D-F) The bar graphs show the mean values,  $\pm$  SD from three  
1056 independent experiments. n.s. indicates no statistical difference between two samples  
1057 as indicated by the horizontal line. C-E) Statistical significance was assessed by one-  
1058 way ANOVA and Tukey's multiple comparison test or F) paired Student's t-test.

1059

1060 **Figure 8. High infectivity of virions produced from MT-4 cells does not explain their**  
1061 **permissivity to gp41 CT-truncation.**

1062 Cells were transduced with VSV-G-pseudotyped NL4-3 encoding either WT or  
1063 CTdel144 Env. Viral supernatant was collected 42 hr post-transduction. Supernatants

1064 were RT normalized, and a serial dilution of virus was used to infect TZM-bl cells.  
1065 Luciferase values were then used to determine the relative infectivity of virus produced  
1066 from each T-cell line. A) The bar graph shows the mean values of CTdel144 relative to  
1067 WT (set at 100),  $\pm$  SD from three independent experiments. B-C) The same virus was  
1068 used as in A) to compare WT and CTdel144 virus infectivity between cell lines. The bar  
1069 graphs show the mean values of B) WT and C) CTdel144 relative to the SupT1  
1070 reference line (set at 100),  $\pm$  SD from three independent experiments. Shading of  
1071 individual columns indicates values for the individual cell lines for ease of comparison  
1072 between data sets in A-C. Statistics relative to the SupT1 reference line, or between two  
1073 samples as indicated by the horizontal line between two bars, are shown. “n.s.”  
1074 indicates no statistical difference between the indicated cell line to the SupT1 reference.  
1075 Statistical significance was assessed by A) Student’s t-test and B) one-way ANOVA and  
1076 Tukey’s multiple comparison test.

1077  
1078 Figure 9. *MT-4 cells express higher levels of surface CT-truncated Env than other T-cell*  
1079 *lines tested as determined by flow cytometry.*

1080 VSV-G-pseudotyped NL4-3 encoding either WT or Ctdel144 Env, or no Env (Env<sup>-</sup>) was  
1081 used to transduce T cells. 40 hours post-transduction, cells were fixed and stained with  
1082 anti-Env antibodies for analysis by flow cytometry. A) Histogram of surface Env for each  
1083 cell line is shown. Env<sup>-</sup> cells were used as a control for background staining. B) Surface  
1084 Env MFI was determined by measuring the MFI value of the Env<sup>+</sup> histogram and  
1085 subtracting the Env<sup>-</sup> MFI to directly compare MFIs between samples. To account for  
1086 fluctuations in flow cytometry data that occur when comparing data from three  
1087 independent experiments, cells were stained with antibody and analyzed in parallel by  
1088 flow cytometry. The bar graph shows the mean values of WT and CTdel144 Env MFI,  $\pm$   
1089 SD from three independent experiments. n.s. indicates no statistical difference between  
1090 WT and CTdel144 for the M8166 cell line. Error bars  $\pm$  SD from 3 independent  
1091 experiments. Statistical significance was assessed by Student’s t-test.

1092  
1093 Figure 10. *MT-4 cells express higher levels of Env than SupT1, which is further*  
1094 *enhanced by truncating the gp41 CT, as determined by confocal microscopy.*

1095 MT-4 or SupT1 cells were infected with a replication-and-release-defective HIV-1  
1096 mutant (described in methods) expressing an eGFP reporter (yellow), and either WT or  
1097 CTdel144 Env. Approximately 40 hours post-infection, cells were simultaneously pulsed  
1098 with anti-Env Fab b12-Atto565 (magenta) and Transferrin-AF647 (blue) for 12 min and  
1099 then chased for 50 min. Cells were fixed and imaged by confocal fluorescence  
1100 microscopy. A) Representative confocal slices of transduced MT-4 or Jurkat E6.1 cells  
1101 after the pulse-chase labeling. Scale bars 15  $\mu$ m, inset scale bars 3  $\mu$ m. B) Total  
1102 surface Env and total internal Env per cell were measured using the integrated  
1103 fluorescence intensity for regions defining the PM of the cell (surface) and a region  
1104 defining the interior of the cell (internal), using a maximum intensity projection through a  
1105 4.5  $\mu$ m confocal range centered in the approximate middle of a single cell. n = 50  
1106 infected cells per sample. The bar graph shows the mean values of Surface and Internal  
1107 Env levels. C) Percent Env internalization was calculated as the percent of internal Env  
1108 above the total Env signal (internal and surface). The scatter plot shows the mean  
1109 values of percent internalized Env. n = 50 infected cells per sample. Error bars  $\pm$  SEM.

1110 Statistical significance was assessed by one-way ANOVA and Tukey's multiple  
1111 comparison test.

1112

1113 Figure 11. *MT-4 serve as better targets for C-C transmission than the other cell lines*  
1114 *tested.*

1115 293T cells were transfected with pBR43leGFP-nef<sup>-</sup> encoding either WT Env or Env<sup>-</sup>.  
1116 Twenty-four hours post-transfection, dye-labelled T cells were either co-cultured or  
1117 added to a transwell exposed to the 293T supernatant. Eighteen hours post-co-culture,  
1118 BMS-806 was added to prevent multiple cycles of infection and the formation of  
1119 syncytia. Forty-four hours post initial co-culture, cells were collected, fixed, and  
1120 analyzed by flow cytometry. A-B) The percentage of cells expressing eGFP was  
1121 determined and plotted. C) The transwell value was subtracted from the co-culture  
1122 value to determine the contribution of cell-to-cell transmission. The bar graphs show the  
1123 mean values of the percent of cells positive for eGFP expression for the A) co-culture,  
1124 B) transwell (cell-free), and C) C-C transmission,  $\pm$  SD from three independent  
1125 experiments. Shading of individual columns indicates values for the cell line for ease of  
1126 comparison between data sets. n.s. indicates no statistically significant difference  
1127 between the indicated cell line and the SupT1 reference or between two samples as  
1128 indicated by the horizontal line connecting two bars. Statistical significance was  
1129 assessed by one-way ANOVA and Tukey's multiple comparison test.

1130

## BIBLIOGRAPHY

- 1131  
1132
- 1133 1. Checkley MA, Luttge BG, Freed EO. 2011. HIV-1 envelope glycoprotein biosynthesis,  
1134 trafficking, and incorporation. *J Mol Biol* 410:582-608.
- 1135 2. Santos da Silva E, Mulinge M, Perez Bercoff D. 2013. The frantic play of the concealed  
1136 HIV envelope cytoplasmic tail. *Retrovirology* 10:54.
- 1137 3. Dufloo J, Bruel T, Schwartz O. 2018. HIV-1 cell-to-cell transmission and broadly  
1138 neutralizing antibodies. *Retrovirology* 15:51.
- 1139 4. Bracq L, Xie M, Benichou S, Bouchet J. 2018. Mechanisms for Cell-to-Cell  
1140 Transmission of HIV-1. *Front Immunol* 9:260.
- 1141 5. Wang L, Izadmehr S, Kamau E, Kong XP, Chen BK. 2019. Sequential trafficking of Env  
1142 and Gag to HIV-1 T cell virological synapses revealed by live imaging. *Retrovirology*  
1143 16:2.
- 1144 6. Zhong P, Agosto LM, Ilinskaya A, Dorjbal B, Truong R, Derse D, Uchil PD, Heidecker  
1145 G, Mothes W. 2013. Cell-to-cell transmission can overcome multiple donor and target  
1146 cell barriers imposed on cell-free HIV. *PLoS One* 8:e53138.
- 1147 7. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ. 2004. HIV-1 cell to cell transfer across  
1148 an Env-induced, actin-dependent synapse. *J Exp Med* 199:283-93.
- 1149 8. Chen P, Hubner W, Spinelli MA, Chen BK. 2007. Predominant mode of human  
1150 immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent  
1151 neutralization-resistant virological synapses. *J Virol* 81:12582-95.
- 1152 9. Law KM, Komarova NL, Yewdall AW, Lee RK, Herrera OL, Wodarz D, Chen BK.  
1153 2016. In Vivo HIV-1 Cell-to-Cell Transmission Promotes Multicopy Micro-  
1154 compartmentalized Infection. *Cell Rep* 15:2771-83.
- 1155 10. Muranyi W, Malkusch S, Muller B, Heilemann M, Krausslich HG. 2013. Super-  
1156 resolution microscopy reveals specific recruitment of HIV-1 envelope proteins to viral  
1157 assembly sites dependent on the envelope C-terminal tail. *PLoS Pathog* 9:e1003198.
- 1158 11. Gardiner JC, Mauer EJ, Sherer NM. 2016. HIV-1 Gag, Envelope, and Extracellular  
1159 Determinants Cooperate To Regulate the Stability and Turnover of Virological Synapses.  
1160 *J Virol* 90:6583-6597.
- 1161 12. Roy NH, Chan J, Lambele M, Thali M. 2013. Clustering and mobility of HIV-1 Env at  
1162 viral assembly sites predict its propensity to induce cell-cell fusion. *J Virol* 87:7516-25.

- 1163 13. Monel B, Beaumont E, Vendrame D, Schwartz O, Brand D, Mammano F. 2012. HIV  
1164 cell-to-cell transmission requires the production of infectious virus particles and does not  
1165 proceed through env-mediated fusion pores. *J Virol* 86:3924-33.
- 1166 14. Emerson V, Haller C, Pfeiffer T, Fackler OT, Bosch V. 2010. Role of the C-terminal  
1167 domain of the HIV-1 glycoprotein in cell-to-cell viral transmission between T  
1168 lymphocytes. *Retrovirology* 7:43.
- 1169 15. Qi M, Williams JA, Chu H, Chen X, Wang JJ, Ding L, Akhrome E, Wen X, Lapierre  
1170 LA, Goldenring JR, Spearman P. 2013. Rab11-FIP1C and Rab14 direct plasma  
1171 membrane sorting and particle incorporation of the HIV-1 envelope glycoprotein  
1172 complex. *PLoS Pathog* 9:e1003278.
- 1173 16. Qi M, Chu H, Chen X, Choi J, Wen X, Hammonds J, Ding L, Hunter E, Spearman P.  
1174 2015. A tyrosine-based motif in the HIV-1 envelope glycoprotein tail mediates cell-type-  
1175 and Rab11-FIP1C-dependent incorporation into virions. *Proc Natl Acad Sci U S A*  
1176 112:7575-80.
- 1177 17. Kirschman J, Qi M, Ding L, Hammonds J, Dienger-Stambaugh K, Wang JJ, Lapierre LA,  
1178 Goldenring JR, Spearman P. 2018. HIV-1 Envelope Glycoprotein Trafficking through the  
1179 Endosomal Recycling Compartment Is Required for Particle Incorporation. *J Virol* 92.
- 1180 18. Postler TS, Desrosiers RC. 2013. The tale of the long tail: the cytoplasmic domain of  
1181 HIV-1 gp41. *J Virol* 87:2-15.
- 1182 19. Buttler CA, Pezeshkian N, Fernandez MV, Aaron J, Norman S, Freed EO, van  
1183 Engelenburg SB. 2018. Single molecule fate of HIV-1 envelope reveals late-stage viral  
1184 lattice incorporation. *Nat Commun* 9:1861.
- 1185 20. Zhu P, Chertova E, Bess J, Jr., Lifson JD, Arthur LO, Liu J, Taylor KA, Roux KH. 2003.  
1186 Electron tomography analysis of envelope glycoprotein trimers on HIV and simian  
1187 immunodeficiency virus virions. *Proc Natl Acad Sci U S A* 100:15812-7.
- 1188 21. Murakami T, Freed EO. 2000. The long cytoplasmic tail of gp41 is required in a cell  
1189 type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. *Proc*  
1190 *Natl Acad Sci U S A* 97:343-8.
- 1191 22. Pezeshkian N, Groves NS, van Engelenburg SB. 2019. Single-molecule imaging of HIV-  
1192 1 envelope glycoprotein dynamics and Gag lattice association exposes determinants  
1193 responsible for virus incorporation. *Proc Natl Acad Sci U S A* 116:25269-25277.
- 1194 23. Tedbury PR, Freed EO. 2014. The role of matrix in HIV-1 envelope glycoprotein  
1195 incorporation. *Trends Microbiol* 22:372-8.



- 1196 24. Bell NM, Lever AM. 2013. HIV Gag polyprotein: processing and early viral particle  
1197 assembly. *Trends Microbiol* 21:136-44.
- 1198 25. Wyma DJ, Kotov A, Aiken C. 2000. Evidence for a stable interaction of gp41 with  
1199 Pr55(Gag) in immature human immunodeficiency virus type 1 particles. *J Virol* 74:9381-  
1200 7.
- 1201 26. Freed EO, Martin MA. 1995. Virion incorporation of envelope glycoproteins with long  
1202 but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in  
1203 the human immunodeficiency virus type 1 matrix. *J Virol* 69:1984-9.
- 1204 27. Tedbury PR, Novikova M, Alfadhli A, Hikichi Y, Kagiampakis I, KewalRamani VN,  
1205 Barklis E, Freed EO. 2019. HIV-1 Matrix Trimerization-Impaired Mutants Are Rescued  
1206 by Matrix Substitutions That Enhance Envelope Glycoprotein Incorporation. *J Virol* 94.
- 1207 28. Tedbury PR, Ablan SD, Freed EO. 2013. Global rescue of defects in HIV-1 envelope  
1208 glycoprotein incorporation: implications for matrix structure. *PLoS Pathog* 9:e1003739.
- 1209 29. Tedbury PR, Mercredi PY, Gaines CR, Summers MF, Freed EO. 2015. Elucidating the  
1210 mechanism by which compensatory mutations rescue an HIV-1 matrix mutant defective  
1211 for gag membrane targeting and envelope glycoprotein incorporation. *J Mol Biol*  
1212 427:1413-1427.
- 1213 30. Ono A, Huang M, Freed EO. 1997. Characterization of human immunodeficiency virus  
1214 type 1 matrix revertants: effects on virus assembly, Gag processing, and Env  
1215 incorporation into virions. *J Virol* 71:4409-18.
- 1216 31. Mammano F, Kondo E, Sodroski J, Bukovsky A, Gottlinger HG. 1995. Rescue of human  
1217 immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with  
1218 short cytoplasmic domains. *J Virol* 69:3824-30.
- 1219 32. Lee YM, Tang XB, Cimasky LM, Hildreth JE, Yu XF. 1997. Mutations in the matrix  
1220 protein of human immunodeficiency virus type 1 inhibit surface expression and virion  
1221 incorporation of viral envelope glycoproteins in CD4+ T lymphocytes. *J Virol* 71:1443-  
1222 52.
- 1223 33. Brandano L, Stevenson M. 2012. A highly conserved residue in the C-terminal helix of  
1224 HIV-1 matrix is required for envelope incorporation into virus particles. *J Virol* 86:2347-  
1225 59.
- 1226 34. Reil H, Bukovsky AA, Gelderblom HR, Gottlinger HG. 1998. Efficient HIV-1 replication  
1227 can occur in the absence of the viral matrix protein. *EMBO J* 17:2699-708.

- 1228 35. Murakami T, Freed EO. 2000. Genetic evidence for an interaction between human  
1229 immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail. *J*  
1230 *Virology* 74:3548-54.
- 1231 36. Wyma DJ, Jiang J, Shi J, Zhou J, Lineberger JE, Miller MD, Aiken C. 2004. Coupling of  
1232 human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the  
1233 gp41 cytoplasmic tail. *J Virology* 78:3429-35.
- 1234 37. Murakami T, Ablan S, Freed EO, Tanaka Y. 2004. Regulation of human  
1235 immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity.  
1236 *J Virology* 78:1026-31.
- 1237 38. Tedbury PR, Novikova M, Ablan SD, Freed EO. 2016. Biochemical evidence of a role  
1238 for matrix trimerization in HIV-1 envelope glycoprotein incorporation. *Proc Natl Acad*  
1239 *Sci U S A* 113:E182-90.
- 1240 39. Jorgenson RL, Vogt VM, Johnson MC. 2009. Foreign glycoproteins can be actively  
1241 recruited to virus assembly sites during pseudotyping. *J Virology* 83:4060-7.
- 1242 40. Sengupta P, Seo AY, Pasolli HA, Song YE, Johnson MC, Lippincott-Schwartz J. 2019. A  
1243 lipid-based partitioning mechanism for selective incorporation of proteins into  
1244 membranes of HIV particles. *Nat Cell Biol* 21:452-461.
- 1245 41. Joshi A, Ablan SD, Soheilian F, Nagashima K, Freed EO. 2009. Evidence that productive  
1246 human immunodeficiency virus type 1 assembly can occur in an intracellular  
1247 compartment. *J Virology* 83:5375-87.
- 1248 42. Holtkotte D, Pfeiffer T, Bosch V. 2007. Cell-free infectivity of HIV type 1 produced in  
1249 nonpermissive cells is only moderately impacted by C-terminal Env truncation despite  
1250 abrogation of viral spread. *AIDS Res Hum Retroviruses* 23:729-40.
- 1251 43. Fernandez MV, Delviks-Frankenberry KA, Scheiblin DA, Happel C, Pathak VK, Freed  
1252 EO. 2019. Authentication Analysis of MT-4 Cells Distributed by the National Institutes  
1253 of Health AIDS Reagent Program. *J Virology* 93.
- 1254 44. Staubus AO, Alfadhli A, Barklis RL, Barklis E. 2019. Replication of HIV-1 envelope  
1255 protein cytoplasmic domain variants in permissive and restrictive cells. *Virology* 538:1-  
1256 10.
- 1257 45. Wilk T, Pfeiffer T, Bosch V. 1992. Retained in vitro infectivity and cytopathogenicity of  
1258 HIV-1 despite truncation of the C-terminal tail of the env gene product. *Virology*  
1259 189:167-77.

- 1260 46. Irwan ID, Karnowski HL, Bogerd HP, Tsai K, Cullen BR. 2020. Reversal of Epigenetic  
1261 Silencing Allows Robust HIV-1 Replication in the Absence of Integrase Function. *mBio*  
1262 11.
- 1263 47. Nakajima N, Lu R, Engelman A. 2001. Human Immunodeficiency Virus Type 1  
1264 Replication in the Absence of Integrase-Mediated DNA Recombination: Definition of  
1265 Permissive and Nonpermissive T-Cell Lines. *Journal of Virology* 75:7944-7955.
- 1266 48. Novikova M, Adams LJ, Fontana J, Gres AT, Balasubramaniam M, Winkler DC,  
1267 Kudchodkar SB, Soheilian F, Sarafianos SG, Steven AC, Freed EO. 2018. Identification  
1268 of a Structural Element in HIV-1 Gag Required for Virus Particle Assembly and  
1269 Maturation. *MBio* 9.
- 1270 49. Day JR, Munk C, Guatelli JC. 2004. The Membrane-Proximal Tyrosine-Based Sorting  
1271 Signal of Human Immunodeficiency Virus Type 1 gp41 Is Required for Optimal Viral  
1272 Infectivity. *Journal of Virology* 78:1069-1079.
- 1273 50. Fochi S, Mutascio S, Bertazzoni U, Zipeto D, Romanelli MG. 2018. HTLV Deregulation  
1274 of the NF-kappaB Pathway: An Update on Tax and Antisense Proteins Role. *Front*  
1275 *Microbiol* 9:285.
- 1276 51. Zimmermann K, Dobrovnik M, Ballaun C, Bevec D, Hauber J, Bohnlein E. 1991. trans-  
1277 activation of the HIV-1 LTR by the HIV-1 Tat and HTLV-I Tax proteins is mediated by  
1278 different cis-acting sequences. *Virology* 182:874-8.
- 1279 52. Lopez CS, Tsagli SM, Sloan R, Eccles J, Barklis E. 2013. Second site reversion of a  
1280 mutation near the amino terminus of the HIV-1 capsid protein. *Virology* 447:95-103.
- 1281 53. Noviello CM, Lopez CS, Kukull B, McNett H, Still A, Eccles J, Sloan R, Barklis E.  
1282 2011. Second-site compensatory mutations of HIV-1 capsid mutations. *J Virol* 85:4730-  
1283 8.
- 1284 54. Tang S, Ablan S, Dueck M, Ayala-Lopez W, Soto B, Caplan M, Nagashima K, Hewlett  
1285 IK, Freed EO, Levin JG. 2007. A second-site suppressor significantly improves the  
1286 defective phenotype imposed by mutation of an aromatic residue in the N-terminal  
1287 domain of the HIV-1 capsid protein. *Virology* 359:105-15.
- 1288 55. Swartz TH, Esposito AM, Durham ND, Hartmann BM, Chen BK. 2014. P2X-selective  
1289 purinergic antagonists are strong inhibitors of HIV-1 fusion during both cell-to-cell and  
1290 cell-free infection. *J Virol* 88:11504-15.
- 1291 56. Soare AY, Durham ND, Gopal R, Tweel B, Hoffman KW, Brown JA, O'Brien M,  
1292 Bhardwaj N, Lim JK, Chen BK, Swartz TH. 2019. P2X Antagonists Inhibit HIV-1

- 1293 Productive Infection and Inflammatory Cytokines Interleukin-10 (IL-10) and IL-1beta in  
1294 a Human Tonsil Explant Model. *J Virol* 93.
- 1295 57. Luo X, He JJ. 2015. Cell-cell contact viral transfer contributes to HIV infection and  
1296 persistence in astrocytes. *J Neurovirol* 21:66-80.
- 1297 58. Akari H, Fukumori T, Adachi A. 2000. Cell-dependent requirement of human  
1298 immunodeficiency virus type 1 gp41 cytoplasmic tail for Env incorporation into virions. *J*  
1299 *Virol* 74:4891-3.
- 1300 59. Smith SD, Shatsky M, Cohen PS, Warnke R, Link MP, Glader BE. 1984. Monoclonal  
1301 antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell  
1302 lines. *Cancer Res* 44:5657-60.
- 1303 60. Schneider U, Schwenk HU, Bornkamm G. 1977. Characterization of EBV-genome  
1304 negative "null" and "T" cell lines derived from children with acute lymphoblastic  
1305 leukemia and leukemic transformed non-Hodgkin lymphoma. *Int J Cancer* 19:621-6.
- 1306 61. Miyoshi I, Taguchi H, Kubonishi I. 1982. Type C virus-producing cell lines derived from  
1307 adult T cell leukemia doi:10.1007/978-1-4615-8336-3\_17.
- 1308 62. Salahuddin SZ, Markham PD, Wong-Staal F, Franchini G, Kalyanaraman VS, Gallo RC.  
1309 1983. Restricted expression of human T-cell leukemia-lymphoma virus (HTLV) in  
1310 transformed human umbilical cord blood lymphocytes. *Virology* 129:51-64.
- 1311 63. Jain P, Mostoller K, Flaig KE, Ahuja J, Lepoutre V, Alefantis T, Khan ZK, Wigdahl B.  
1312 2007. Identification of human T cell leukemia virus type 1 tax amino acid signals and  
1313 cellular factors involved in secretion of the viral oncoprotein. *J Biol Chem* 282:34581-93.
- 1314 64. Baba M, Okamoto M, Hamasaki T, Horai S, Wang X, Ito Y, Suda Y, Arima N. 2008.  
1315 Highly enhanced expression of CD70 on human T-lymphotropic virus type 1-carrying T-  
1316 cell lines and adult T-cell leukemia cells. *J Virol* 82:3843-52.
- 1317 65. Raimondi V, Minuzzo S, Ciminale V, D'Agostino DM. 2017. STR Profiling of HTLV-1-  
1318 Infected Cell Lines. *Methods Mol Biol* 1582:143-154.
- 1319 66. Bellas RE, Li Y. 1996. A Block to Efficient Replication of Simian Immunodeficiency  
1320 Virus in C8166 Cells Can Be Overcome by Duplication of the NF-kappaB Binding Site. *J*  
1321 *Biomed Sci* 3:415-421.
- 1322 67. Kamada K, Igarashi T, Martin MA, Khamisri B, Hatcho K, Yamashita T, Fujita M,  
1323 Uchiyama T, Adachi A. 2006. Generation of HIV-1 derivatives that productively infect  
1324 macaque monkey lymphoid cells. *Proc Natl Acad Sci U S A* 103:16959-64.

- 1325 68. Shudofsky AMD, Giam CZ. 2019. Cells of adult T-cell leukemia evade HTLV-1  
1326 Tax/NF-kappaB hyperactivation-induced senescence. *Blood Adv* 3:564-569.
- 1327 69. Zhi H, Yang L, Kuo YL, Ho YK, Shih HM, Giam CZ. 2011. NF-kappaB hyper-  
1328 activation by HTLV-1 tax induces cellular senescence, but can be alleviated by the viral  
1329 anti-sense protein HBZ. *PLoS Pathog* 7:e1002025.
- 1330 70. Yang Y, Wu J, Wang J. 2016. A database and functional annotation of NF- $\kappa$ B target  
1331 genes. *9:7986-7995*.
- 1332 71. Rouillard AD, Gundersen GW, Fernandez NF, Wang Z, Monteiro CD, McDermott MG,  
1333 Ma'ayan A. 2016. The harmonizome: a collection of processed datasets gathered to serve  
1334 and mine knowledge about genes and proteins. *Database* 2016.
- 1335 72. Consortium EP. 2011. A user's guide to the encyclopedia of DNA elements (ENCODE).  
1336 *PLoS Biol* 9:e1001046.
- 1337 73. Berlioz-Torrent C, Shacklett BL, Erdtmann L, Delamarre L, Bouchaert I, Sonigo P,  
1338 Dokhelar MC, Benarous R. 1999. Interactions of the cytoplasmic domains of human and  
1339 simian retroviral transmembrane proteins with components of the clathrin adaptor  
1340 complexes modulate intracellular and cell surface expression of envelope glycoproteins. *J*  
1341 *Virol* 73:1350-61.
- 1342 74. Egan MA, Carruth LM, Rowell JF, Yu X, Siliciano RF. 1996. Human immunodeficiency  
1343 virus type 1 envelope protein endocytosis mediated by a highly conserved intrinsic  
1344 internalization signal in the cytoplasmic domain of gp41 is suppressed in the presence of  
1345 the Pr55gag precursor protein. *J Virol* 70:6547-56.
- 1346 75. Ohno H, Aguilar RC, Fournier MC, Hennecke S, Cosson P, Bonifacino JS. 1997.  
1347 Interaction of endocytic signals from the HIV-1 envelope glycoprotein complex with  
1348 members of the adaptor medium chain family. *Virology* 238:305-15.
- 1349 76. Durham ND, Yewdall AW, Chen P, Lee R, Zony C, Robinson JE, Chen BK. 2012.  
1350 Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by  
1351 the gp41 cytoplasmic tail. *J Virol* 86:7484-95.
- 1352 77. Anand SP, Grover JR, Tolbert WD, Prevost J, Richard J, Ding S, Baril S, Medjahed H,  
1353 Evans DT, Pazgier M, Mothes W, Finzi A. 2019. Antibody-Induced Internalization of  
1354 HIV-1 Env Proteins Limits Surface Expression of the Closed Conformation of Env. *J*  
1355 *Virol* 93.


- 1356 78. Jing SQ, Spencer T, Miller K, Hopkins C, Trowbridge IS. 1990. Role of the human  
1357 transferrin receptor cytoplasmic domain in endocytosis: localization of a specific signal  
1358 sequence for internalization. *The Journal of cell biology* 110:283-294.
- 1359 79. Nesterov A, Carter RE, Sorkina T, Gill GN, Sorkin A. 1999. Inhibition of the receptor-  
1360 binding function of clathrin adaptor protein AP-2 by dominant-negative mutant mu2  
1361 subunit and its effects on endocytosis. *The EMBO journal* 18:2489-2499.
- 1362 80. Puigdomenech I, Massanella M, Izquierdo-Useros N, Ruiz-Hernandez R, Curriu M,  
1363 Bofill M, Martinez-Picado J, Juan M, Clotet B, Blanco J. 2008. HIV transfer between  
1364 CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the  
1365 interaction of HIV envelope glycoprotein with CD4. *Retrovirology* 5:32.
- 1366 81. Emerson V, Holtkotte D, Pfeiffer T, Wang IH, Schnolzer M, Kempf T, Bosch V. 2010.  
1367 Identification of the cellular prohibitin 1/prohibitin 2 heterodimer as an interaction  
1368 partner of the C-terminal cytoplasmic domain of the HIV-1 glycoprotein. *J Virol*  
1369 84:1355-65.
- 1370 82. Samal S, Das S, Boliar S, Qureshi H, Shrivastava T, Kumar N, Goswami S, Bansal M,  
1371 Chakrabarti BK. 2018. Cell surface ectodomain integrity of a subset of functional HIV-1  
1372 envelopes is dependent on a conserved hydrophilic domain containing region in their C-  
1373 terminal tail. *Retrovirology* 15:50.
- 1374 83. Hogan MJ, Conde-Motter A, Jordan APO, Yang L, Cleveland B, Guo W, Romano J, Ni  
1375 H, Pardi N, LaBranche CC, Montefiori DC, Hu SL, Hoxie JA, Weissman D. 2018.  
1376 Increased surface expression of HIV-1 envelope is associated with improved antibody  
1377 response in vaccinia prime/protein boost immunization. *Virology* 514:106-117.
- 1378 84. Waheed AA, Freed EO. 2009. Lipids and membrane microdomains in HIV-1 replication.  
1379 *Virus Res* 143:162-76.
- 1380 85. Dumas F, Haanappel E. 2017. Lipids in infectious diseases - The case of AIDS and  
1381 tuberculosis. *Biochim Biophys Acta Biomembr* 1859:1636-1647.
- 1382 86. Means RE, Matthews T, Hoxie JA, Malim MH, Kodama T, Desrosiers RC. 2001. Ability  
1383 of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-  
1384 mediated neutralization: correlation of neutralization sensitivity, growth in macrophages,  
1385 and decreased dependence on CD4. *J Virol* 75:3903-15.
- 1386 87. Freed EO, Delwart EL, Buchschacher GL, Jr., Panganiban AT. 1992. A mutation in the  
1387 human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly  
1388 interferes with fusion and infectivity. *Proc Natl Acad Sci U S A* 89:70-4.

- 1389 88. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986.  
1390 Production of acquired immunodeficiency syndrome-associated retrovirus in human and  
1391 nonhuman cells transfected with an infectious molecular clone. *J Virol* 59:284-91.
- 1392 89. Huang M, Orenstein JM, Martin MA, Freed EO. 1995. p6Gag is required for particle  
1393 production from full-length human immunodeficiency virus type 1 molecular clones  
1394 expressing protease. *J Virol* 69:6810-8.
- 1395 90. Van Engelenburg SB, Shtengel G, Sengupta P, Waki K, Jarnik M, Ablan SD, Freed EO,  
1396 Hess HF, Lippincott-Schwartz J. 2014. Distribution of ESCRT machinery at HIV  
1397 assembly sites reveals virus scaffolding of ESCRT subunits. *Science* 343:653-6.
- 1398 91. Yee JK, Friedmann T, Burns JC. 1994. Generation of high-titer pseudotyped retroviral  
1399 vectors with very broad host range. *Methods Cell Biol* 43 Pt A:99-112.
- 1400 92. Tanabe H, Takada Y, Minegishi D, Kurematsu M, Masui T, Mizusawa H. 1999. Cell line  
1401 individualization by STR Multiplex System in the cell bank found cross-contamination  
1402 between ECV304 AND EJ-1/T24. *Tissue Culture Research Communications* 18:329-338.
- 1403 93. Freed EO, Martin MA. 1994. Evidence for a functional interaction between the V1/V2  
1404 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120.  
1405 *J Virol* 68:2503-12.
- 1406 94. Cavrois M, De Noronha C, Greene WC. 2002. A sensitive and specific enzyme-based  
1407 assay detecting HIV-1 virion fusion in primary T lymphocytes. *Nat Biotechnol* 20:1151-  
1408 4.
- 1409 95. Van Duyne R, Kuo LS, Pham P, Fujii K, Freed EO. 2019. Mutations in the HIV-1  
1410 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication  
1411 cycle. *Proc Natl Acad Sci U S A* 116:9040-9049.
- 1412 96. Barbas CF, 3rd, Bjorling E, Chiodi F, Dunlop N, Cababa D, Jones TM, Zebedee SL,  
1413 Persson MA, Nara PL, Norrby E, et al. 1992. Recombinant human Fab fragments  
1414 neutralize human type 1 immunodeficiency virus in vitro. *Proc Natl Acad Sci U S A*  
1415 89:9339-43.
- 1416 97. Platonova E, Winterflood CM, Junemann A, Albrecht D, Faix J, Ewers H. 2015. Single-  
1417 molecule microscopy of molecules tagged with GFP or RFP derivatives in mammalian  
1418 cells using nanobody binders. *Methods* 88:89-97.
- 1419 98. Barbas CF, 3rd, Collet TA, Amberg W, Roben P, Binley JM, Hoekstra D, Cababa D,  
1420 Jones TM, Williamson RA, Pilkington GR, et al. 1993. Molecular profile of an antibody  
1421 response to HIV-1 as probed by combinatorial libraries. *J Mol Biol* 230:812-23.

- 1422 99. Gillis S, Watson J. 1980. Biochemical and biological characterization of lymphocyte  
1423 regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T  
1424 cell line. *J Exp Med* 152:1709-19.
- 1425 100. Weiss A, Wiskocil RL, Stobo JD. 1984. The role of T3 surface molecules in the  
1426 activation of human T cells: a two-stimulus requirement for IL 2 production reflects  
1427 events occurring at a pre-translational level. *J Immunol* 133:123-8.
- 1428 101. Harada S, Koyanagi Y, Yamamoto N. 1985. Infection of HTLV-III/LAV in HTLV-I-  
1429 carrying cells MT-2 and MT-4 and application in a plaque assay. *Science* 229:563-6.
- 1430 102. Poiesz BJ, Ruscetti FW, Reitz MS, Kalyanaraman VS, Gallo RC. 1981. Isolation of a  
1431 new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sezary T-cell  
1432 leukaemia. *Nature* 294:268-71.
- 1433 103. Gazdar AF, Carney DN, Bunn PA, Russell EK, Jaffe ES, Schechter GP, Guccion JG.  
1434 1980. Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas.  
1435 *Blood* 55:409-17.
- 1436 104. Manzari V, Wong-Staal F, Franchini G, Colombini S, Gelmann EP, Oroszlan S, Staal S,  
1437 Gallo RC. 1983. Human T-cell leukemia-lymphoma virus (HTLV): cloning of an  
1438 integrated defective provirus and flanking cellular sequences. *Proc Natl Acad Sci U S A*  
1439 80:1574-8.
- 1440 105. Clapham PR, Weiss RA, Dalgleish AG, Exley M, Whitby D, Hogg N. 1987. Human  
1441 immunodeficiency virus infection of monocytic and T-lymphocytic cells: receptor  
1442 modulation and differentiation induced by phorbol ester. *Virology* 158:44-51.  
1443  
1444




# Figure 1.




**TABLE 1. T-cell Line STR profiles**

| <b>Genetic Loci</b>              | <b>Jurkat E6.1</b> | <b>MT-4</b> | <b>C8166 &amp; M8166</b> | <b>SupT1</b>   |
|----------------------------------|--------------------|-------------|--------------------------|----------------|
| D3S1358                          | 15, 17             | 17          | 15,16                    | 16, 17, 18, 19 |
| TH01                             | 6, 9.3             | 7           | 6, 9.3                   | 9.3            |
| D21S11                           | 30.2, 31.2, 33.2   | 28, 30.3    | 27, 30                   | 28, 31, 32, 33 |
| D18S51                           | 12, 13, 20, 21     | 13          | 14, 17                   | 13, 14         |
| Penta E                          | 10, 12             | 5, 15       | 7, 11                    | 13, 14, 16     |
| D5S818                           | 9                  | 10, 11      | 12                       | 11             |
| D13S317                          | 8, 12              | 12          | 10, 11                   | 10, 11, 12     |
| D7S820                           | 8, 12              | 8, 10       | 9, 10                    | 11             |
| D16S539                          | 11                 | 9, 12       | 12, 13                   | 9, 12          |
| CSF1PO                           | 10, 11, 12, 13     | 11, 12      | 10                       | 10, 11, 12     |
| Penta D                          | 11, 13             | 10, 13      | 11, 15                   | 12             |
| vWA                              | 18, 19             | 17, 18      | 15, 16                   | 16,17,18,19    |
| D8S1179                          | 12, 13, 14, 15     | 10, 15      | 11, 14                   | 13,14          |
| TPOX                             | 8, 10              | 11          | 11                       | 9              |
| FGA                              | 20, 21             | 23          | 21, 22                   | 19, 20, 21     |
| AMEL                             | X,Y                | X,Y         | X,Y                      | X,Y            |
|                                  |                    |             |                          |                |
| % Match to Cellosaurus reference | 87.88              | 100         | 98.31                    | 82.35          |
|                                  |                    |             |                          |                |
| source                           | NIH-ARP            | NIH-ARP     | NIH-ARP                  | unknown        |
| catalog no.                      | 177                | 120         | 404 & 11395              |                |


## Figure 2.




### Figure 3.




## Figure 4.



## Figure 5.




## Figure 6.




## Figure 7.


### A) SupT1




### D)




### B) MT-4




### E)



### F)




### C)






## Figure 8.


A)





B)




C)



## Figure 9.



# Figure 10.



## Figure 11.

